Pancreatic Agenesis

Mendelian MONDO:0009832 Pathograph 15 Show in embeddings browser hereditary disease disorder of development or morphogenesis

Pancreatic agenesis is a rare congenital developmental disorder in which the pancreas is absent or markedly hypoplastic. Complete pancreatic agenesis usually presents with permanent neonatal diabetes from severe insulin deficiency and exocrine pancreatic insufficiency requiring enzyme replacement. Known Mendelian causes disrupt pancreatic developmental transcription-factor dosage or regulation, especially GATA6, PTF1A, and PDX1. A fourth cause, biallelic loss of the primate-specific epigenetic silencer ZNF808, acts instead by derepressing the transposable elements it normally keeps silent during early pancreas development.

Ask OpenScientist

Ask a research question about Pancreatic Agenesis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
3
Inheritance
6
Pathophys.
10
Phenotypes
15
Pathograph
4
Genes
3
Medical Actions
4
Subtypes
1
Models
1
References
1
Deep Research
📘

Definitions

1
Pancreas agenesis clinical definition
A rare condition underlying a variant of permanent neonatal diabetes in which complete pancreatic agenesis restricts fetal growth and causes neonatal endocrine and exocrine pancreatic failure.
OTHER
Show evidence (1 reference)
PMID:38180040 SUPPORT Human Clinical
"Pancreas agenesis is a rare condition underlying a variant of permanent neonatal diabetes mellitus."
The 2024 semiquantitative analysis gives a concise disease definition and links pancreas agenesis to permanent neonatal diabetes.
👪

Inheritance

3
Autosomal dominant GATA6-associated pancreatic agenesis HP:0000006
GATA6-associated pancreatic agenesis is usually heterozygous and often de novo, consistent with haploinsufficiency.
autosomal dominant inheritance
Show evidence (1 reference)
PMID:22158542 SUPPORT Human Clinical
"We report de novo heterozygous inactivating mutations in GATA6 in 15/27 (56%) individuals with pancreatic agenesis."
The discovery cohort supports a heterozygous, frequently de novo GATA6 inheritance pattern for a major subset of pancreatic agenesis.
Autosomal recessive PTF1A or PDX1-associated pancreatic agenesis HP:0000007
PTF1A coding or enhancer defects and severe PDX1/IPF1 variants typically require biallelic loss of function for complete pancreatic agenesis.
autosomal recessive inheritance
Show evidence (1 reference)
PMID:22158542 SUPPORT Human Clinical
"This is in contrast to PDX1 and PTF1A mutations, where pancreatic agenesis results from a complete absence of functional protein as a result of homozygous inactivating mutations."
The GATA6 discovery paper distinguishes heterozygous GATA6 disease from homozygous PDX1/PTF1A-related pancreatic agenesis.
Autosomal recessive ZNF808-associated pancreatic agenesis HP:0000007
ZNF808-related pancreatic agenesis requires biallelic loss of function. Reported families are homozygous for the variant and it cosegregates with disease as a recessive trait.
autosomal recessive inheritance
Show evidence (1 reference)
PMID:37973953 SUPPORT Human Clinical
"All families showed cosegregation of the ZNF808 homozygous variants with the disease consistent with recessive inheritance"
Cosegregation of the homozygous variant with disease in every reported family is the direct statement of recessive inheritance.
◆

Subtypes

4
GATA6-Related Pancreatic Agenesis MONDO:0100540
21 of 39 (54%) patients with pancreatic agenesis in the combined neonatal diabetes cohorts GATA6 hgnc:4174 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in GATA6 (hgnc:4174). hgnc:4174 is a gene from the HUGO Gene Nomenclature Committee. Autosomal dominant inheritance MONDO MONDO:0100540
Heterozygous, frequently de novo inactivating GATA6 variants: the most commonly identified molecular cause of pancreatic agenesis in neonatal diabetes cohorts, and the form regularly accompanied by congenital heart and other endodermal-organ malformations. MONDO files GATA6 pancreatic involvement under a congenital heart disease class rather than under pancreatic agenesis, so no child of the parent term is available to bind as this row's subtype_term.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"we have now identified GATA6 mutations in 21 of 39 (54%) patients with pancreatic agenesis"
Quantifies the share of pancreatic agenesis cases this subtype row carries, which is the figure in subtype_frequency.
Pancreatic Agenesis 1 (PDX1-Related) MONDO:0024547
PDX1 hgnc:6107 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in PDX1 (hgnc:6107). hgnc:6107 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Pancreatic agenesis from biallelic variants in PDX1, the gene formerly called IPF1. MONDO defines this class as any pancreatic agenesis whose cause is a mutation in PDX1 and cross-references it to OMIM:260370.
Show evidence (1 reference)
PMID:12970316 SUPPORT Human Clinical
"Here, we describe two novel mutations in the IPF1 gene leading to pancreas agenesis."
IPF1 is the former symbol for PDX1, so this report is the human evidence that the gene defining this subtype causes pancreatic agenesis.
Pancreatic Agenesis 2 (PTF1A-Related) MONDO:0014406
PTF1A hgnc:23734 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in PTF1A (hgnc:23734). hgnc:23734 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Pancreatic agenesis from biallelic PTF1A coding, splice-site, or distal enhancer variants. MONDO defines this class as any pancreatic agenesis whose cause is a mutation in PTF1A and cross-references it to OMIM:615935. Because the causal variant can lie in the noncoding enhancer, exome sequencing alone can miss it.
Show evidence (1 reference)
PMID:40443916 SUPPORT Human Clinical
"One of the rarest causes of NDM is pancreatic agenesis, which results from mutations affecting the pancreas transcription factor 1A (PTF1A) gene and its enhancer."
Names PTF1A and its enhancer as the cause of the pancreatic agenesis form this subtype row carries.
Pancreatic Agenesis 3 (ZNF808-Related) MONDO:0975839
ZNF808 hgnc:33230 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in ZNF808 (hgnc:33230). hgnc:33230 is a gene from the HUGO Gene Nomenclature Committee. Autosomal recessive inheritance
Pancreatic agenesis from biallelic loss of ZNF808, a KRAB zinc finger protein that silences primate-specific transposable elements during early pancreas development. MONDO cross-references this class to OMIM:620991. The gene is primate-specific, so the mechanism was established in human in vitro pancreatic differentiation rather than in a knockout mouse, and no extrapancreatic feature was consistently observed in the reported cohort.
Show evidence (2 references)
PMID:37973953 SUPPORT Human Clinical
"Here, we report the identification of homozygous loss-of-function variants in the primate-specific gene ZNF808 as a cause of pancreatic agenesis."
The discovery report names ZNF808 biallelic loss of function as a cause of pancreatic agenesis, which is what this subtype row asserts.
PMID:37973953 SUPPORT Human Clinical
"no extra-pancreatic features were consistently observed in the cohort."
Supports the statement in this row that the phenotype is confined to the pancreas, which is what separates it from the GATA6 row.
⚙

Pathophysiology

6
GATA6 Haploinsufficiency
Heterozygous GATA6 loss-of-function variants reduce pancreatic developmental transcription-factor dosage and can cause pancreatic agenesis.
pancreatic epithelial cell CL:0000083 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves pancreatic epithelial cell, annotated with epithelial cell of pancreas (CL:0000083). CL:0000083 is a cell type from the Cell Ontology.
GATA6 hgnc:4174 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GATA6 (hgnc:4174). hgnc:4174 is a gene from the HUGO Gene Nomenclature Committee.
pancreas development GO:0031016 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased pancreas development (GO:0031016). GO:0031016 is a biological process from the Gene Ontology.
Downstream
Endocrine and Exocrine Pancreatic Tissue Deficiency GATA6 haploinsufficiency disrupts pancreas development, producing absent or hypoplastic endocrine and exocrine tissue.
Show evidence (2 references)
PMID:22158542 SUPPORT Human Clinical
"Therefore, we found GATA6 mutations to be present in the majority (15/27 (56%)) of subjects with pancreatic agenesis."
The human cohort identifies GATA6 variants as the most common molecular cause in affected pancreatic agenesis subjects.
PMID:22158542 SUPPORT In Vitro
"The functional studies of missense DNA-binding-domain mutations and the identification of frameshift and splicing mutations suggest that heterozygous GATA6 mutations result in loss of function and cause pancreatic agenesis through haploinsufficiency."
Functional assays and variant classes support GATA6 haploinsufficiency as a distinct upstream mechanism.
PTF1A Coding or Enhancer Disruption
Biallelic PTF1A coding, splice-site, or enhancer variants reduce PTF1A activity or expression below the developmental threshold needed for pancreas organogenesis.
pancreatic epithelial cell CL:0000083 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves pancreatic epithelial cell, annotated with epithelial cell of pancreas (CL:0000083). CL:0000083 is a cell type from the Cell Ontology.
PTF1A hgnc:23734 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PTF1A (hgnc:23734). hgnc:23734 is a gene from the HUGO Gene Nomenclature Committee.
pancreas development GO:0031016 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased pancreas development (GO:0031016). GO:0031016 is a biological process from the Gene Ontology.
Downstream
Endocrine and Exocrine Pancreatic Tissue Deficiency PTF1A disruption impairs pancreatic organogenesis, leading to absent pancreatic tissue and combined endocrine-exocrine deficiency.
Show evidence (2 references)
PMID:22158542 SUPPORT Human Clinical
"We found one affected subject to have a homozygous PTF1A splice site mutation, but we identified no mutations in PDX1 in this cohort."
The cohort documents a PTF1A splice-site etiology distinct from GATA6 haploinsufficiency.
PMID:40443916 SUPPORT Human Clinical
"Molecular analysis revealed homozygosity for the g.23508437A > G variant within the enhancer region of the PTF1A gene."
This case report supports noncoding PTF1A enhancer disruption as a separate upstream mechanism.
PDX1 Protein Destabilization
Biallelic IPF1/PDX1 homeodomain variants can reduce protein stability and transcriptional activity, impairing the pancreatic transcriptional program.
pancreatic epithelial cell CL:0000083 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves pancreatic epithelial cell, annotated with epithelial cell of pancreas (CL:0000083). CL:0000083 is a cell type from the Cell Ontology.
PDX1 hgnc:6107 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PDX1 (hgnc:6107). hgnc:6107 is a gene from the HUGO Gene Nomenclature Committee.
pancreas development GO:0031016 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased pancreas development (GO:0031016). GO:0031016 is a biological process from the Gene Ontology.
Downstream
Endocrine and Exocrine Pancreatic Tissue Deficiency Reduced PDX1 protein stability impairs pancreas formation and downstream endocrine and exocrine tissue development.
Show evidence (2 references)
PMID:12970316 SUPPORT Human Clinical
"Here, we describe two novel mutations in the IPF1 gene leading to pancreas agenesis."
IPF1 is the historical name for PDX1, and this human report links PDX1 variants directly to pancreatic agenesis.
PMID:12970316 SUPPORT In Vitro
"Mutations localized in helices 1 and 2, respectively, of the homeodomain, decreased the protein half-life significantly, leading to intracellular IPF1 levels of 36% and 27% of wild-type levels."
Functional assays show reduced IPF1/PDX1 protein abundance, separating this mechanism from dosage loss or enhancer disruption.
ZNF808 Loss and Transposable Element Derepression
ZNF808 is a KRAB zinc finger protein that silences a family of primate-specific transposable elements. When both alleles are lost those elements are no longer repressed during early pancreas development and the regulatory potential they carry is aberrantly activated.
ZNF808 hgnc:33230 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ZNF808 (hgnc:33230). hgnc:33230 is a gene from the HUGO Gene Nomenclature Committee.
transposable element silencing GO:0010526 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased transposable element silencing (GO:0010526). GO:0010526 is a biological process from the Gene Ontology.
Downstream
Endodermal Fate Misspecification Toward Hepatic Identity The derepressed elements supply regulatory input during early pancreas development, which is how loss of silencing reaches cell fate.
Show evidence (2 references)
PMID:37973953 SUPPORT BACKGROUND Other
"ZNF808 is a member of the KRAB zinc finger protein family, a large and rapidly evolving group of epigenetic silencers which target transposable elements."
States the protein-family identity and silencing activity that this node says is lost. The sentence reports no experiment, so it is graded as background rather than as a study result.
PMID:37973953 SUPPORT PRIMARY RESULT In Vitro
"We show that loss of ZNF808 in vitro results in aberrant activation of regulatory potential contained in the primate-specific transposable elements it represses during early pancreas development. This leads to inappropriate specification of cell fate with induction of genes associated with liver..."
The differentiation experiment shows loss of transposable element silencing on ZNF808 loss, which is the process bound on this node.
Endodermal Fate Misspecification Toward Hepatic Identity
With the primate-specific transposable elements derepressed, endodermal cell fate specification during early pancreas development is redirected: genes associated with liver identity are induced in place of the pancreatic program.
endodermal cell fate specification GO:0001714 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal endodermal cell fate specification (GO:0001714). GO:0001714 is a biological process from the Gene Ontology.
Downstream
Endocrine and Exocrine Pancreatic Tissue Deficiency Pancreatic progenitors specified to the wrong identity leave the pancreas absent or severely hypoplastic, so both endocrine and exocrine tissue is deficient.
Show evidence (1 reference)
PMID:37973953 SUPPORT PRIMARY RESULT In Vitro
"We show that loss of ZNF808 in vitro results in aberrant activation of regulatory potential contained in the primate-specific transposable elements it represses during early pancreas development. This leads to inappropriate specification of cell fate with induction of genes associated with liver..."
The same experiment reports the second step: cell fate specification going to liver identity rather than pancreas, which is the process bound here.
Endocrine and Exocrine Pancreatic Tissue Deficiency
Absent or markedly hypoplastic pancreas produces severe neonatal insulin deficiency and exocrine pancreatic insufficiency. These downstream consequences drive neonatal diabetes, malabsorption, and the need for insulin and enzyme replacement therapy.
pancreatic epithelial cell CL:0000083 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves pancreatic epithelial cell, annotated with epithelial cell of pancreas (CL:0000083). CL:0000083 is a cell type from the Cell Ontology.
insulin secretion GO:0030073 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased insulin secretion (GO:0030073). GO:0030073 is a biological process from the Gene Ontology. pancreatic juice secretion GO:0030157 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased pancreatic juice secretion (GO:0030157). GO:0030157 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:23223019 SUPPORT Human Clinical
"Pancreatic imaging had been undertaken in 18 of 21 pancreatic agenesis case subjects and showed complete absence (n = 8) or marked hypoplasia (n = 10) of the pancreas."
Imaging data in the GATA6 cohort directly document absent or severely underdeveloped pancreas.
PMID:23223019 SUPPORT Human Clinical
"Measurement of fecal elastase or fecal fat in 15 case subjects showed severe exocrine pancreatic insufficiency."
The cohort documents downstream exocrine failure in pancreatic agenesis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pancreatic Agenesis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Cardiovascular 1
Congenital Heart Defects Abnormal heart morphology HP:0001627 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congenital heart defect, annotated with Abnormal heart morphology (HP:0001627). HP:0001627 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"Congenital heart defects are most common, present in 21 of 24 probands and three parents (83%), and required surgical correction in 19 case subjects."
This supports congenital heart defects as a frequent extrapancreatic feature of GATA6-associated disease.
Digestive 5
Pancreatic Agenesis or Hypoplasia Aplasia/Hypoplasia of the pancreas HP:0100800 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aplasia/Hypoplasia of the pancreas (HP:0100800). HP:0100800 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"Pancreatic imaging had been undertaken in 18 of 21 pancreatic agenesis case subjects and showed complete absence (n = 8) or marked hypoplasia (n = 10) of the pancreas."
This supports the structural pancreatic agenesis/hypoplasia phenotype.
Exocrine Pancreatic Insufficiency HP:0001738 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Exocrine pancreatic insufficiency (HP:0001738). HP:0001738 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"Measurement of fecal elastase or fecal fat in 15 case subjects showed severe exocrine pancreatic insufficiency."
Fecal elastase or fat testing confirms severe exocrine pancreatic insufficiency in affected patients.
Hepatobiliary Malformations Abnormal biliary tract morphology HP:0012440 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is hepatobiliary malformations, annotated with Abnormal biliary tract morphology (HP:0012440). HP:0012440 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"Additional extrapancreatic features in the probands include congenital hypothyroidism (n = 6), hepatobiliary malformations (in particular gallbladder agenesis and biliary atresia, n = 5), and gut abnormalities (intestinal malrotation and hernias, n = 6). Eleven patients also have a significant..."
The cohort reports hepatobiliary malformations in 5 of 24 probands.
Intestinal Malrotation and Hernias HP:0002566 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intestinal malrotation (HP:0002566). HP:0002566 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"Additional extrapancreatic features in the probands include congenital hypothyroidism (n = 6), hepatobiliary malformations (in particular gallbladder agenesis and biliary atresia, n = 5), and gut abnormalities (intestinal malrotation and hernias, n = 6). Eleven patients also have a significant..."
The cohort reports gut abnormalities, specifically intestinal malrotation and hernias, in 6 of 24 probands.
Steatorrhea HP:0002570 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Steatorrhea (HP:0002570). HP:0002570 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"Measurement of fecal elastase or fecal fat in 15 case subjects showed severe exocrine pancreatic insufficiency."
Fecal fat measurement directly supports fat malabsorption in the context of severe exocrine pancreatic insufficiency, though the abstract does not name steatorrhea itself.
Endocrine 2
Neonatal Diabetes Mellitus Neonatal insulin-dependent diabetes mellitus HP:0000857 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal insulin-dependent diabetes mellitus (HP:0000857). HP:0000857 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"The median age at diagnosis of diabetes for the 24 probands with GATA6 mutations was 2 days"
The cohort documents neonatal onset of diabetes in GATA6-associated pancreatic agenesis.
Congenital Hypothyroidism HP:0000851 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congenital hypothyroidism (HP:0000851). HP:0000851 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"Additional extrapancreatic features in the probands include congenital hypothyroidism (n = 6), hepatobiliary malformations (in particular gallbladder agenesis and biliary atresia, n = 5), and gut abnormalities (intestinal malrotation and hernias, n = 6). Eleven patients also have a significant..."
The GATA6 cohort reports congenital hypothyroidism in 6 of 24 probands.
Nervous System 1
Neurodevelopmental Deficit Neurodevelopmental delay HP:0012758 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neurodevelopmental delay (HP:0012758). HP:0012758 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"Additional extrapancreatic features in the probands include congenital hypothyroidism (n = 6), hepatobiliary malformations (in particular gallbladder agenesis and biliary atresia, n = 5), and gut abnormalities (intestinal malrotation and hernias, n = 6). Eleven patients also have a significant..."
The cohort reports significant neurocognitive deficit in 11 of 24 probands.
Growth 1
Intrauterine Growth Retardation HP:0001511 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intrauterine growth retardation (HP:0001511). HP:0001511 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38180040 SUPPORT Human Clinical
"In conclusion, pancreas agenesis severely restricts fetal length and head circumference in addition to weight growth, with stronger effects evident from 36 weeks of gestation."
The semiquantitative case analysis supports prenatal growth restriction affecting multiple anthropometric measures.
🧬

Genetic Associations

4
GATA6 pathogenic variants (Causative)
Gene: GATA6 hgnc:4174 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GATA6 (hgnc:4174). hgnc:4174 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:22158542 SUPPORT Human Clinical
"These findings define the most common cause of human pancreatic agenesis and establish a key role for the transcription factor GATA6 in human pancreatic development."
This cohort establishes GATA6 as a high-confidence causal gene for human pancreatic agenesis.
PMID:23223019 SUPPORT Human Clinical
"In total, we have now identified GATA6 mutations in 21 of 39 (54%) patients with pancreatic agenesis (6 case subjects in this study and 15 reported by Lango Allen et al. [1])."
The expanded neonatal diabetes cohort quantifies the frequency of GATA6 mutations among patients with pancreatic agenesis.
PTF1A pathogenic coding or enhancer variants (Causative)
Gene: PTF1A hgnc:23734 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PTF1A (hgnc:23734). hgnc:23734 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:40443916 SUPPORT Human Clinical
"One of the rarest causes of NDM is pancreatic agenesis, which results from mutations affecting the pancreas transcription factor 1A (PTF1A) gene and its enhancer."
This 2025 case report and review identifies PTF1A and its enhancer as causes of pancreatic agenesis with neonatal diabetes.
PMID:40443916 SUPPORT Human Clinical
"Molecular analysis revealed homozygosity for the g.23508437A > G variant within the enhancer region of the PTF1A gene."
The cited patient demonstrates a homozygous PTF1A enhancer variant associated with pancreatic agenesis.
PDX1 pathogenic variants (Causative)
Gene: PDX1 hgnc:6107 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PDX1 (hgnc:6107). hgnc:6107 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:12970316 SUPPORT Human Clinical
"Here, we describe two novel mutations in the IPF1 gene leading to pancreas agenesis."
IPF1 is the historical name for PDX1, and this human report links PDX1 variants directly to pancreatic agenesis.
ZNF808 pathogenic variants (Causative)
Gene: ZNF808 hgnc:33230 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ZNF808 (hgnc:33230). hgnc:33230 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:37973953 SUPPORT Human Clinical
"Here, we report the identification of homozygous loss-of-function variants in the primate-specific gene ZNF808 as a cause of pancreatic agenesis."
The discovery report names biallelic ZNF808 loss of function as a cause of pancreatic agenesis in humans.
PMID:37973953 SUPPORT Human Clinical
"No deleterious homozygous loss-of-function ZNF808 variants were identified in >680,000 individuals without neonatal diabetes or pancreatic agenesis"
Absence of the biallelic loss-of-function genotype from large unaffected population datasets is the population-genetic support for causality.
💊

Medical Actions

3
Insulin Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: insulin CHEBI:145810 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses insulin (CHEBI:145810). CHEBI:145810 is a therapeutic agent from Chemical Entities of Biological Interest.
Insulin replacement treats neonatal diabetes caused by absent or severely reduced endocrine pancreatic tissue.
Mechanism Target:
RESTORES Endocrine and Exocrine Pancreatic Tissue Deficiency — Insulin therapy replaces the endocrine function lost when pancreatic tissue is absent or markedly hypoplastic.
Target Phenotypes: Neonatal insulin-dependent diabetes mellitus HP:0000857 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Neonatal insulin-dependent diabetes mellitus (HP:0000857). HP:0000857 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40443916 SUPPORT Human Clinical
"At two years of age, with pancreatic enzyme replacement and insulin therapy, the patient exhibits normal neurological development, and his physical growth is at the 38th percentile."
The abstract documents insulin therapy as part of successful supportive management in a PTF1A enhancer pancreatic agenesis case.
Pancreatic Enzyme Replacement
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: Pancrelipase NCIT:C29345 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Pancrelipase (NCIT:C29345). NCIT:C29345 is a therapeutic agent from the NCI Thesaurus.
Pancreatic enzyme replacement addresses exocrine pancreatic insufficiency from absent exocrine tissue and supports growth and nutrition.
Mechanism Target:
RESTORES Endocrine and Exocrine Pancreatic Tissue Deficiency — Pancreatic enzyme replacement restores digestive enzyme activity missing because exocrine pancreatic tissue is absent or severely deficient.
Target Phenotypes: Exocrine pancreatic insufficiency HP:0001738 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Exocrine pancreatic insufficiency (HP:0001738). HP:0001738 is a phenotype from the Human Phenotype Ontology. Steatorrhea HP:0002570 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Steatorrhea (HP:0002570). HP:0002570 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40443916 SUPPORT Human Clinical
"At two years of age, with pancreatic enzyme replacement and insulin therapy, the patient exhibits normal neurological development, and his physical growth is at the 38th percentile."
The case report documents pancreatic enzyme replacement as part of management for pancreatic agenesis with exocrine insufficiency.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Families benefit from gene-specific counseling because pancreatic agenesis includes de novo dominant GATA6 disease and autosomal recessive PTF1A/PDX1 disease.
Show evidence (1 reference)
PMID:40443916 SUPPORT Human Clinical
"Therefore, targeted evaluation of PTF1A is essential when a genetic etiology is suspected."
The need for targeted genetic evaluation supports gene-informed family counseling and recurrence-risk assessment.
🔬

Diagnosis

2
Pancreatic imaging
Abdominal ultrasound and MRI can demonstrate absent pancreatic tissue or marked hypoplasia in infants with neonatal diabetes and exocrine insufficiency.
Show evidence (1 reference)
PMID:40443916 SUPPORT Human Clinical
"Hyperglycemia was detected from the first day of life, and ultrasonography confirmed the absence of pancreatic tissue."
This case report supports ultrasound as a diagnostic method for absent pancreatic tissue.
Molecular genetic testing
Genetic testing should evaluate pancreatic developmental transcription factors and, when PTF1A is suspected, include enhancer-region assessment because exome sequencing can miss noncoding causes.
Show evidence (1 reference)
PMID:40443916 SUPPORT Human Clinical
"While whole-exome sequencing (WES) remains the gold standard for genetic diagnosis, it may fail to detect certain mutations."
The report warns that WES can miss relevant PTF1A enhancer mutations.
📈

Progression

1
Neonatal presentation
Age: Birth to first weeks of life
Diabetes is typically detected in the neonatal period, with the GATA6 cohort showing a median diagnosis at 2 days.
Show evidence (1 reference)
PMID:23223019 SUPPORT Human Clinical
"The median age at diagnosis of diabetes for the 24 probands with GATA6 mutations was 2 days"
This supports neonatal clinical onset in affected probands.
🐁

Animal Models

1
Hlxb9 deficiency Mus musculus Genetic model
Hlxb9-deficient mice develop selective dorsal pancreatic agenesis, providing a partial-agenesis developmental model for disrupted pancreatic bud specification.
pancreatic agenesis or hypoplasia
Species
Mus musculus
Genotype
Hlxb9 deficiency
Show evidence (1 reference)
PMID:10471501 SUPPORT Model Organism
"In absence of Hlxb9 expression, the dorsal region of the gut epithelium fails to initiate a pancreatic differentiation program."
This mouse model recapitulates regional pancreatic developmental failure but models dorsal rather than complete pancreatic agenesis.
{ }

Source YAML

click to show 
name: Pancreatic Agenesis
creation_date: "2026-05-09T13:53:48Z"
category: Mendelian
synonyms:
- pancreas agenesis
- complete pancreatic agenesis
- pancreatic aplasia
- congenital pancreatic agenesis
- pancreatic agenesis type 1
- partial agenesis of the pancreas
- partial pancreatic agenesis
description: >-
  Pancreatic agenesis is a rare congenital developmental disorder in which the
  pancreas is absent or markedly hypoplastic. Complete pancreatic agenesis
  usually presents with permanent neonatal diabetes from severe insulin
  deficiency and exocrine pancreatic insufficiency requiring enzyme
  replacement. Known Mendelian causes disrupt pancreatic developmental
  transcription-factor dosage or regulation, especially GATA6, PTF1A, and PDX1.
  A fourth cause, biallelic loss of the primate-specific epigenetic silencer
  ZNF808, acts instead by derepressing the transposable elements it normally
  keeps silent during early pancreas development.
disease_term:
  preferred_term: pancreatic agenesis
  term:
    id: MONDO:0009832
    label: pancreatic agenesis
parents:
- hereditary disease
- disorder of development or morphogenesis
has_subtypes:
- name: GATA6
  display_name: GATA6-Related Pancreatic Agenesis
  classification: molecular
  description: >-
    Heterozygous, frequently de novo inactivating GATA6 variants: the most
    commonly identified molecular cause of pancreatic agenesis in neonatal
    diabetes cohorts, and the form regularly accompanied by congenital heart
    and other endodermal-organ malformations. MONDO files GATA6 pancreatic
    involvement under a congenital heart disease class rather than under
    pancreatic agenesis, so no child of the parent term is available to bind
    as this row's subtype_term.
  subtype_frequency: 21 of 39 (54%) patients with pancreatic agenesis in the combined neonatal diabetes cohorts
  genes:
  - preferred_term: GATA6
    term:
      id: hgnc:4174
      label: GATA6
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0100540
        label: GATA6-related congenital heart disease with or without pancreatic hypoplasia or diabetes
      mapping_predicate: skos:broadMatch
      mapping_source: MONDO
      mapping_justification: >-
        A synonym-inclusive search of the gene symbol
        (runoak -i ols:mondo search "GATA6") returns MONDO:0100540 as the only
        GATA6 class covering pancreatic involvement. Its hierarchical parents are
        MONDO:0005453 congenital heart disease and MONDO:0100547 cardiogenetic
        disease, not MONDO:0009832, so it is a broader cardiac-led concept rather
        than a pancreatic agenesis subtype. Recorded as broadMatch, which leaves
        the concept in the curation queue.
  inheritance:
  - name: Autosomal dominant inheritance
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    description: >-
      A single inactivating GATA6 allele is sufficient, and the variant is
      usually de novo rather than inherited.
    evidence:
    - reference: PMID:22158542
      reference_title: GATA6 haploinsufficiency causes pancreatic agenesis in humans.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We report de novo heterozygous inactivating mutations in GATA6 in 15/27
        (56%) individuals with pancreatic agenesis.
      explanation: >-
        The discovery cohort establishes the heterozygous, frequently de novo
        pattern that makes this subtype autosomal dominant.
  evidence:
  - reference: PMID:23223019
    reference_title: >-
      GATA6 mutations cause a broad phenotypic spectrum of diabetes from
      pancreatic agenesis to adult-onset diabetes without exocrine
      insufficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we have now identified GATA6 mutations in 21 of 39 (54%) patients with
      pancreatic agenesis
    explanation: >-
      Quantifies the share of pancreatic agenesis cases this subtype row
      carries, which is the figure in subtype_frequency.
- name: PAGEN1
  display_name: Pancreatic Agenesis 1 (PDX1-Related)
  classification: molecular
  subtype_term:
    preferred_term: pancreatic agenesis 1
    term:
      id: MONDO:0024547
      label: pancreatic agenesis 1
  description: >-
    Pancreatic agenesis from biallelic variants in PDX1, the gene formerly
    called IPF1. MONDO defines this class as any pancreatic agenesis whose
    cause is a mutation in PDX1 and cross-references it to OMIM:260370.
  genes:
  - preferred_term: PDX1
    term:
      id: hgnc:6107
      label: PDX1
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    description: >-
      Complete pancreatic agenesis from PDX1 requires loss of functional
      protein from both alleles.
    evidence:
    - reference: PMID:22158542
      reference_title: GATA6 haploinsufficiency causes pancreatic agenesis in humans.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This is in contrast to PDX1 and PTF1A mutations, where pancreatic
        agenesis results from a complete absence of functional protein as a result
        of homozygous inactivating mutations.
      explanation: >-
        States that pancreatic agenesis from PDX1 follows homozygous
        inactivating mutations, which is autosomal recessive transmission.
    - reference: PMID:20301620
      reference_title: Permanent Neonatal Diabetes Mellitus.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: >-
        PDX1-, PTF1A-, RFX6-, SLC2A2-, and SLC19A2-related PNDM are inherited in
        an autosomal recessive manner.
      explanation: >-
        The GeneReviews chapter for permanent neonatal diabetes assigns
        autosomal recessive inheritance to PDX1-related disease by gene name.
  evidence:
  - reference: PMID:12970316
    reference_title: >-
      Agenesis of human pancreas due to decreased half-life of insulin promoter
      factor 1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we describe two novel mutations in the IPF1 gene leading to pancreas
      agenesis.
    explanation: >-
      IPF1 is the former symbol for PDX1, so this report is the human evidence
      that the gene defining this subtype causes pancreatic agenesis.
- name: PAGEN2
  display_name: Pancreatic Agenesis 2 (PTF1A-Related)
  classification: molecular
  subtype_term:
    preferred_term: pancreatic agenesis 2
    term:
      id: MONDO:0014406
      label: pancreatic agenesis 2
  description: >-
    Pancreatic agenesis from biallelic PTF1A coding, splice-site, or distal
    enhancer variants. MONDO defines this class as any pancreatic agenesis whose
    cause is a mutation in PTF1A and cross-references it to OMIM:615935. Because
    the causal variant can lie in the noncoding enhancer, exome sequencing alone
    can miss it.
  genes:
  - preferred_term: PTF1A
    term:
      id: hgnc:23734
      label: PTF1A
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    description: >-
      Both PTF1A alleles must be affected, whether by coding or by enhancer
      variants.
    evidence:
    - reference: PMID:40443916
      reference_title: >-
        A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with
        Pancreatic Agenesis: Case Report and Considerations for Genetic
        Evaluation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Molecular analysis revealed homozygosity for the g.23508437A > G variant
        within the enhancer region of the PTF1A gene.
      explanation: >-
        The reported patient is homozygous for the causal enhancer variant,
        which is recessive transmission.
    - reference: PMID:20301620
      reference_title: Permanent Neonatal Diabetes Mellitus.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: >-
        PDX1-, PTF1A-, RFX6-, SLC2A2-, and SLC19A2-related PNDM are inherited in
        an autosomal recessive manner.
      explanation: >-
        The GeneReviews chapter for permanent neonatal diabetes assigns
        autosomal recessive inheritance to PTF1A-related disease by gene name.
  evidence:
  - reference: PMID:40443916
    reference_title: >-
      A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with
      Pancreatic Agenesis: Case Report and Considerations for Genetic
      Evaluation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One of the rarest causes of NDM is pancreatic agenesis, which results from
      mutations affecting the pancreas transcription factor 1A (PTF1A) gene and
      its enhancer.
    explanation: >-
      Names PTF1A and its enhancer as the cause of the pancreatic agenesis form
      this subtype row carries.
- name: PAGEN3
  display_name: Pancreatic Agenesis 3 (ZNF808-Related)
  classification: molecular
  subtype_term:
    preferred_term: pancreatic agenesis 3
    term:
      id: MONDO:0975839
      label: pancreatic agenesis 3
  description: >-
    Pancreatic agenesis from biallelic loss of ZNF808, a KRAB zinc finger
    protein that silences primate-specific transposable elements during early
    pancreas development. MONDO cross-references this class to OMIM:620991. The
    gene is primate-specific, so the mechanism was established in human in vitro
    pancreatic differentiation rather than in a knockout mouse, and no
    extrapancreatic feature was consistently observed in the reported cohort.
  genes:
  - preferred_term: ZNF808
    term:
      id: hgnc:33230
      label: ZNF808
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    description: >-
      Affected individuals are homozygous for ZNF808 loss-of-function alleles,
      and the variants cosegregate with disease as a recessive trait.
    evidence:
    - reference: PMID:37973953
      reference_title: >-
        Primate-specific ZNF808 is essential for pancreatic development in
        humans.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        All families showed cosegregation of the ZNF808 homozygous variants with
        the disease consistent with recessive inheritance
      explanation: >-
        Cosegregation of homozygous variants across all reported families is the
        direct statement of recessive inheritance for this subtype.
  evidence:
  - reference: PMID:37973953
    reference_title: >-
      Primate-specific ZNF808 is essential for pancreatic development in
      humans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report the identification of homozygous loss-of-function variants
      in the primate-specific gene ZNF808 as a cause of pancreatic agenesis.
    explanation: >-
      The discovery report names ZNF808 biallelic loss of function as a cause of
      pancreatic agenesis, which is what this subtype row asserts.
  - reference: PMID:37973953
    reference_title: >-
      Primate-specific ZNF808 is essential for pancreatic development in
      humans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      no extra-pancreatic features were consistently observed in the cohort.
    explanation: >-
      Supports the statement in this row that the phenotype is confined to the
      pancreas, which is what separates it from the GATA6 row.
definitions:
- name: Pancreas agenesis clinical definition
  definition_type: OTHER
  description: >-
    A rare condition underlying a variant of permanent neonatal diabetes in
    which complete pancreatic agenesis restricts fetal growth and causes
    neonatal endocrine and exocrine pancreatic failure.
  evidence:
  - reference: PMID:38180040
    reference_title: "Pancreas agenesis and fetal growth: a semi-quantitative analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pancreas agenesis is a rare condition underlying a variant of permanent
      neonatal diabetes mellitus.
    explanation: >-
      The 2024 semiquantitative analysis gives a concise disease definition
      and links pancreas agenesis to permanent neonatal diabetes.
inheritance:
- name: Autosomal dominant GATA6-associated pancreatic agenesis
  inheritance_term:
    preferred_term: autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    GATA6-associated pancreatic agenesis is usually heterozygous and often de
    novo, consistent with haploinsufficiency.
  evidence:
  - reference: PMID:22158542
    reference_title: "GATA6 haploinsufficiency causes pancreatic agenesis in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report de novo heterozygous inactivating mutations in GATA6 in 15/27
      (56%) individuals with pancreatic agenesis.
    explanation: >-
      The discovery cohort supports a heterozygous, frequently de novo GATA6
      inheritance pattern for a major subset of pancreatic agenesis.
- name: Autosomal recessive PTF1A or PDX1-associated pancreatic agenesis
  inheritance_term:
    preferred_term: autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    PTF1A coding or enhancer defects and severe PDX1/IPF1 variants typically
    require biallelic loss of function for complete pancreatic agenesis.
  evidence:
  - reference: PMID:22158542
    reference_title: "GATA6 haploinsufficiency causes pancreatic agenesis in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is in contrast to PDX1 and PTF1A mutations, where pancreatic
      agenesis results from a complete absence of functional protein as a result
      of homozygous inactivating mutations.
    explanation: >-
      The GATA6 discovery paper distinguishes heterozygous GATA6 disease from
      homozygous PDX1/PTF1A-related pancreatic agenesis.
- name: Autosomal recessive ZNF808-associated pancreatic agenesis
  inheritance_term:
    preferred_term: autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    ZNF808-related pancreatic agenesis requires biallelic loss of function.
    Reported families are homozygous for the variant and it cosegregates with
    disease as a recessive trait.
  evidence:
  - reference: PMID:37973953
    reference_title: >-
      Primate-specific ZNF808 is essential for pancreatic development in
      humans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All families showed cosegregation of the ZNF808 homozygous variants with
      the disease consistent with recessive inheritance
    explanation: >-
      Cosegregation of the homozygous variant with disease in every reported
      family is the direct statement of recessive inheritance.
genetic:
- name: GATA6 pathogenic variants
  gene_term:
    preferred_term: GATA6
    term:
      id: hgnc:4174
      label: GATA6
  association: Causative
  relationship_type: CAUSATIVE
  subtype: GATA6
  variant_origin: GERMLINE
  features: >-
    Heterozygous inactivating GATA6 variants are the most common known cause of
    pancreatic agenesis in neonatal diabetes cohorts and are frequently
    accompanied by congenital heart and other endodermal-organ malformations.
  evidence:
  - reference: PMID:22158542
    reference_title: "GATA6 haploinsufficiency causes pancreatic agenesis in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings define the most common cause of human pancreatic agenesis
      and establish a key role for the transcription factor GATA6 in human
      pancreatic development.
    explanation: >-
      This cohort establishes GATA6 as a high-confidence causal gene for human
      pancreatic agenesis.
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In total, we have now identified GATA6 mutations in 21 of 39 (54%)
      patients with pancreatic agenesis (6 case subjects in this study and 15
      reported by Lango Allen et al. [1]).
    explanation: >-
      The expanded neonatal diabetes cohort quantifies the frequency of GATA6
      mutations among patients with pancreatic agenesis.
- name: PTF1A pathogenic coding or enhancer variants
  gene_term:
    preferred_term: PTF1A
    term:
      id: hgnc:23734
      label: PTF1A
  association: Causative
  relationship_type: CAUSATIVE
  subtype: PAGEN2
  variant_origin: GERMLINE
  features: >-
    Biallelic PTF1A coding or enhancer-region variants cause a rare neonatal
    diabetes phenotype with pancreatic agenesis. Noncoding enhancer variants
    can be missed by exome sequencing.
  evidence:
  - reference: PMID:40443916
    reference_title: "A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One of the rarest causes of NDM is pancreatic agenesis, which results from
      mutations affecting the pancreas transcription factor 1A (PTF1A) gene and
      its enhancer.
    explanation: >-
      This 2025 case report and review identifies PTF1A and its enhancer as
      causes of pancreatic agenesis with neonatal diabetes.
  - reference: PMID:40443916
    reference_title: "A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Molecular analysis revealed homozygosity for the g.23508437A > G variant
      within the enhancer region of the PTF1A gene.
    explanation: >-
      The cited patient demonstrates a homozygous PTF1A enhancer variant
      associated with pancreatic agenesis.
- name: PDX1 pathogenic variants
  gene_term:
    preferred_term: PDX1
    term:
      id: hgnc:6107
      label: PDX1
  association: Causative
  relationship_type: CAUSATIVE
  subtype: PAGEN1
  variant_origin: GERMLINE
  features: >-
    Severe biallelic PDX1/IPF1 variants can cause complete pancreatic agenesis;
    milder hypomorphic alleles can present elsewhere on the monogenic diabetes
    spectrum.
  evidence:
  - reference: PMID:12970316
    reference_title: "Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we describe two novel mutations in the IPF1 gene leading to pancreas
      agenesis.
    explanation: >-
      IPF1 is the historical name for PDX1, and this human report links PDX1
      variants directly to pancreatic agenesis.
- name: ZNF808 pathogenic variants
  gene_term:
    preferred_term: ZNF808
    term:
      id: hgnc:33230
      label: ZNF808
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: PAGEN3
  features: >-
    Biallelic loss-of-function variants in ZNF808, a primate-specific KRAB zinc
    finger gene with no rodent counterpart, cause pancreatic agenesis. No
    homozygous deleterious loss-of-function variant was found in more than
    680,000 individuals without neonatal diabetes or pancreatic agenesis, so the
    allele class is effectively absent from unaffected populations.
  evidence:
  - reference: PMID:37973953
    reference_title: >-
      Primate-specific ZNF808 is essential for pancreatic development in
      humans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report the identification of homozygous loss-of-function variants
      in the primate-specific gene ZNF808 as a cause of pancreatic agenesis.
    explanation: >-
      The discovery report names biallelic ZNF808 loss of function as a cause of
      pancreatic agenesis in humans.
  - reference: PMID:37973953
    reference_title: >-
      Primate-specific ZNF808 is essential for pancreatic development in
      humans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No deleterious homozygous loss-of-function ZNF808 variants were identified
      in >680,000 individuals without neonatal diabetes or pancreatic agenesis
    explanation: >-
      Absence of the biallelic loss-of-function genotype from large unaffected
      population datasets is the population-genetic support for causality.
pathophysiology:
- name: GATA6 Haploinsufficiency
  description: >-
    Heterozygous GATA6 loss-of-function variants reduce pancreatic
    developmental transcription-factor dosage and can cause pancreatic agenesis.
  genes:
  - preferred_term: GATA6
    term:
      id: hgnc:4174
      label: GATA6
  cell_types:
  - preferred_term: pancreatic epithelial cell
    term:
      id: CL:0000083
      label: epithelial cell of pancreas
  biological_processes:
  - preferred_term: pancreas development
    term:
      id: GO:0031016
      label: pancreas development
    modifier: DECREASED
  evidence:
  - reference: PMID:22158542
    reference_title: "GATA6 haploinsufficiency causes pancreatic agenesis in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, we found GATA6 mutations to be present in the majority (15/27
      (56%)) of subjects with pancreatic agenesis.
    explanation: >-
      The human cohort identifies GATA6 variants as the most common molecular
      cause in affected pancreatic agenesis subjects.
  - reference: PMID:22158542
    reference_title: "GATA6 haploinsufficiency causes pancreatic agenesis in humans."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The functional studies of missense DNA-binding-domain mutations and the
      identification of frameshift and splicing mutations suggest that
      heterozygous GATA6 mutations result in loss of function and cause
      pancreatic agenesis through haploinsufficiency.
    explanation: >-
      Functional assays and variant classes support GATA6 haploinsufficiency as
      a distinct upstream mechanism.
  downstream:
  - target: Endocrine and Exocrine Pancreatic Tissue Deficiency
    description: >-
      GATA6 haploinsufficiency disrupts pancreas development, producing absent or
      hypoplastic endocrine and exocrine tissue.
- name: PTF1A Coding or Enhancer Disruption
  description: >-
    Biallelic PTF1A coding, splice-site, or enhancer variants reduce PTF1A
    activity or expression below the developmental threshold needed for pancreas
    organogenesis.
  genes:
  - preferred_term: PTF1A
    term:
      id: hgnc:23734
      label: PTF1A
  cell_types:
  - preferred_term: pancreatic epithelial cell
    term:
      id: CL:0000083
      label: epithelial cell of pancreas
  biological_processes:
  - preferred_term: pancreas development
    term:
      id: GO:0031016
      label: pancreas development
    modifier: DECREASED
  evidence:
  - reference: PMID:22158542
    reference_title: "GATA6 haploinsufficiency causes pancreatic agenesis in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found one affected subject to have a homozygous PTF1A splice site
      mutation, but we identified no mutations in PDX1 in this cohort.
    explanation: >-
      The cohort documents a PTF1A splice-site etiology distinct from GATA6
      haploinsufficiency.
  - reference: PMID:40443916
    reference_title: "A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Molecular analysis revealed homozygosity for the g.23508437A > G variant
      within the enhancer region of the PTF1A gene.
    explanation: >-
      This case report supports noncoding PTF1A enhancer disruption as a separate
      upstream mechanism.
  downstream:
  - target: Endocrine and Exocrine Pancreatic Tissue Deficiency
    description: >-
      PTF1A disruption impairs pancreatic organogenesis, leading to absent
      pancreatic tissue and combined endocrine-exocrine deficiency.
- name: PDX1 Protein Destabilization
  description: >-
    Biallelic IPF1/PDX1 homeodomain variants can reduce protein stability and
    transcriptional activity, impairing the pancreatic transcriptional program.
  genes:
  - preferred_term: PDX1
    term:
      id: hgnc:6107
      label: PDX1
  cell_types:
  - preferred_term: pancreatic epithelial cell
    term:
      id: CL:0000083
      label: epithelial cell of pancreas
  biological_processes:
  - preferred_term: pancreas development
    term:
      id: GO:0031016
      label: pancreas development
    modifier: DECREASED
  evidence:
  - reference: PMID:12970316
    reference_title: "Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we describe two novel mutations in the IPF1 gene leading to pancreas
      agenesis.
    explanation: >-
      IPF1 is the historical name for PDX1, and this human report links PDX1
      variants directly to pancreatic agenesis.
  - reference: PMID:12970316
    reference_title: "Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Mutations localized in helices 1 and 2, respectively, of the homeodomain,
      decreased the protein half-life significantly, leading to intracellular
      IPF1 levels of 36% and 27% of wild-type levels.
    explanation: >-
      Functional assays show reduced IPF1/PDX1 protein abundance, separating this
      mechanism from dosage loss or enhancer disruption.
  downstream:
  - target: Endocrine and Exocrine Pancreatic Tissue Deficiency
    description: >-
      Reduced PDX1 protein stability impairs pancreas formation and downstream
      endocrine and exocrine tissue development.
- name: ZNF808 Loss and Transposable Element Derepression
  description: >-
    ZNF808 is a KRAB zinc finger protein that silences a family of
    primate-specific transposable elements. When both alleles are lost those
    elements are no longer repressed during early pancreas development and the
    regulatory potential they carry is aberrantly activated.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: ZNF808
    term:
      id: hgnc:33230
      label: ZNF808
  biological_processes:
  - preferred_term: transposable element silencing
    term:
      id: GO:0010526
      label: transposable element silencing
    modifier: DECREASED
  evidence:
  - reference: PMID:37973953
    reference_title: >-
      Primate-specific ZNF808 is essential for pancreatic development in
      humans.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: BACKGROUND
    snippet: >-
      ZNF808 is a member of the KRAB zinc finger protein family, a large and
      rapidly evolving group of epigenetic silencers which target transposable
      elements.
    explanation: >-
      States the protein-family identity and silencing activity that this node
      says is lost. The sentence reports no experiment, so it is graded as
      background rather than as a study result.
  - reference: PMID:37973953
    reference_title: >-
      Primate-specific ZNF808 is essential for pancreatic development in
      humans.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: >-
      We show that loss of ZNF808 in vitro results in aberrant activation of
      regulatory potential contained in the primate-specific transposable
      elements it represses during early pancreas development. This leads to
      inappropriate specification of cell fate with induction of genes
      associated with liver identity.
    explanation: >-
      The differentiation experiment shows loss of transposable element
      silencing on ZNF808 loss, which is the process bound on this node.
  downstream:
  - target: Endodermal Fate Misspecification Toward Hepatic Identity
    description: >-
      The derepressed elements supply regulatory input during early pancreas
      development, which is how loss of silencing reaches cell fate.
- name: Endodermal Fate Misspecification Toward Hepatic Identity
  description: >-
    With the primate-specific transposable elements derepressed, endodermal cell
    fate specification during early pancreas development is redirected: genes
    associated with liver identity are induced in place of the pancreatic
    program.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: endodermal cell fate specification
    term:
      id: GO:0001714
      label: endodermal cell fate specification
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37973953
    reference_title: >-
      Primate-specific ZNF808 is essential for pancreatic development in
      humans.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: >-
      We show that loss of ZNF808 in vitro results in aberrant activation of
      regulatory potential contained in the primate-specific transposable
      elements it represses during early pancreas development. This leads to
      inappropriate specification of cell fate with induction of genes
      associated with liver identity.
    explanation: >-
      The same experiment reports the second step: cell fate specification going
      to liver identity rather than pancreas, which is the process bound here.
  downstream:
  - target: Endocrine and Exocrine Pancreatic Tissue Deficiency
    description: >-
      Pancreatic progenitors specified to the wrong identity leave the pancreas
      absent or severely hypoplastic, so both endocrine and exocrine tissue is
      deficient.
- name: Endocrine and Exocrine Pancreatic Tissue Deficiency
  description: >-
    Absent or markedly hypoplastic pancreas produces severe neonatal insulin
    deficiency and exocrine pancreatic insufficiency. These downstream
    consequences drive neonatal diabetes, malabsorption, and the need for
    insulin and enzyme replacement therapy.
  cell_types:
  - preferred_term: pancreatic epithelial cell
    term:
      id: CL:0000083
      label: epithelial cell of pancreas
  biological_processes:
  - preferred_term: insulin secretion
    term:
      id: GO:0030073
      label: insulin secretion
    modifier: DECREASED
  - preferred_term: pancreatic juice secretion
    term:
      id: GO:0030157
      label: pancreatic juice secretion
    modifier: DECREASED
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pancreatic imaging had been undertaken in 18 of 21 pancreatic agenesis
      case subjects and showed complete absence (n = 8) or marked hypoplasia (n
      = 10) of the pancreas.
    explanation: >-
      Imaging data in the GATA6 cohort directly document absent or severely
      underdeveloped pancreas.
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Measurement of fecal elastase or fecal fat in 15 case subjects showed
      severe exocrine pancreatic insufficiency.
    explanation: >-
      The cohort documents downstream exocrine failure in pancreatic agenesis.
phenotypes:
- name: Pancreatic Agenesis or Hypoplasia
  category: Morphological
  description: >-
    Congenital absence or marked hypoplasia of pancreatic tissue on imaging.
  phenotype_term:
    preferred_term: Aplasia/Hypoplasia of the pancreas
    term:
      id: HP:0100800
      label: Aplasia/Hypoplasia of the pancreas
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pancreatic imaging had been undertaken in 18 of 21 pancreatic agenesis
      case subjects and showed complete absence (n = 8) or marked hypoplasia (n
      = 10) of the pancreas.
    explanation: >-
      This supports the structural pancreatic agenesis/hypoplasia phenotype.
- name: Neonatal Diabetes Mellitus
  category: Endocrine
  description: >-
    Insulin-requiring diabetes usually presents in the first days of life when
    endocrine pancreatic tissue is absent or severely reduced.
  phenotype_term:
    preferred_term: Neonatal insulin-dependent diabetes mellitus
    term:
      id: HP:0000857
      label: Neonatal insulin-dependent diabetes mellitus
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median age at diagnosis of diabetes for the 24 probands with GATA6
      mutations was 2 days
    explanation: >-
      The cohort documents neonatal onset of diabetes in GATA6-associated
      pancreatic agenesis.
- name: Exocrine Pancreatic Insufficiency
  category: Gastrointestinal
  description: >-
    Exocrine enzyme deficiency causes maldigestion and requires pancreatic
    enzyme replacement; steatorrhea can occur when fat absorption is impaired.
  phenotype_term:
    preferred_term: Exocrine pancreatic insufficiency
    term:
      id: HP:0001738
      label: Exocrine pancreatic insufficiency
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Measurement of fecal elastase or fecal fat in 15 case subjects showed
      severe exocrine pancreatic insufficiency.
    explanation: >-
      Fecal elastase or fat testing confirms severe exocrine pancreatic
      insufficiency in affected patients.
- name: Intrauterine Growth Retardation
  category: Growth
  description: >-
    Complete pancreatic agenesis restricts fetal weight, length, and head
    circumference growth, likely reflecting absent fetal insulin effects.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: PMID:38180040
    reference_title: "Pancreas agenesis and fetal growth: a semi-quantitative analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In conclusion, pancreas agenesis severely restricts fetal length and head
      circumference in addition to weight growth, with stronger effects evident
      from 36 weeks of gestation.
    explanation: >-
      The semiquantitative case analysis supports prenatal growth restriction
      affecting multiple anthropometric measures.
- name: Congenital Heart Defects
  category: Cardiovascular
  description: >-
    Congenital heart defects are common in GATA6-associated pancreatic agenesis
    and can require surgical repair.
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Congenital heart defects are most common, present in 21 of 24 probands and
      three parents (83%), and required surgical correction in 19 case subjects.
    explanation: >-
      This supports congenital heart defects as a frequent extrapancreatic
      feature of GATA6-associated disease.
- name: Congenital Hypothyroidism
  category: Endocrine
  description: >-
    Congenital hypothyroidism is a recurrent extrapancreatic endocrine feature in
    GATA6-associated pancreatic agenesis.
  phenotype_term:
    preferred_term: Congenital hypothyroidism
    term:
      id: HP:0000851
      label: Congenital hypothyroidism
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional extrapancreatic features in the probands include congenital
      hypothyroidism (n = 6), hepatobiliary malformations (in particular
      gallbladder agenesis and biliary atresia, n = 5), and gut abnormalities
      (intestinal malrotation and hernias, n = 6). Eleven patients also have a
      significant neurocognitive deficit.
    explanation: >-
      The GATA6 cohort reports congenital hypothyroidism in 6 of 24 probands.
- name: Hepatobiliary Malformations
  category: Gastrointestinal
  description: >-
    Hepatobiliary malformations, including gallbladder agenesis and biliary
    atresia, are recurrent extrapancreatic features of GATA6-associated disease.
  phenotype_term:
    preferred_term: hepatobiliary malformations
    term:
      id: HP:0012440
      label: Abnormal biliary tract morphology
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional extrapancreatic features in the probands include congenital
      hypothyroidism (n = 6), hepatobiliary malformations (in particular
      gallbladder agenesis and biliary atresia, n = 5), and gut abnormalities
      (intestinal malrotation and hernias, n = 6). Eleven patients also have a
      significant neurocognitive deficit.
    explanation: >-
      The cohort reports hepatobiliary malformations in 5 of 24 probands.
- name: Intestinal Malrotation and Hernias
  category: Gastrointestinal
  description: >-
    Gut developmental abnormalities in GATA6-associated disease include
    intestinal malrotation and hernias.
  phenotype_term:
    preferred_term: Intestinal malrotation
    term:
      id: HP:0002566
      label: Intestinal malrotation
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional extrapancreatic features in the probands include congenital
      hypothyroidism (n = 6), hepatobiliary malformations (in particular
      gallbladder agenesis and biliary atresia, n = 5), and gut abnormalities
      (intestinal malrotation and hernias, n = 6). Eleven patients also have a
      significant neurocognitive deficit.
    explanation: >-
      The cohort reports gut abnormalities, specifically intestinal malrotation
      and hernias, in 6 of 24 probands.
- name: Neurodevelopmental Deficit
  category: Neurologic
  description: >-
    Significant neurocognitive deficits are reported in a substantial subset of
    GATA6-associated pancreatic agenesis probands.
  phenotype_term:
    preferred_term: Neurodevelopmental delay
    term:
      id: HP:0012758
      label: Neurodevelopmental delay
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional extrapancreatic features in the probands include congenital
      hypothyroidism (n = 6), hepatobiliary malformations (in particular
      gallbladder agenesis and biliary atresia, n = 5), and gut abnormalities
      (intestinal malrotation and hernias, n = 6). Eleven patients also have a
      significant neurocognitive deficit.
    explanation: >-
      The cohort reports significant neurocognitive deficit in 11 of 24 probands.
- name: Steatorrhea
  category: Gastrointestinal
  description: >-
    Fat malabsorption can accompany exocrine pancreatic insufficiency.
  phenotype_term:
    preferred_term: Steatorrhea
    term:
      id: HP:0002570
      label: Steatorrhea
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Measurement of fecal elastase or fecal fat in 15 case subjects showed
      severe exocrine pancreatic insufficiency.
    explanation: >-
      Fecal fat measurement directly supports fat malabsorption in the context of
      severe exocrine pancreatic insufficiency, though the abstract does not name
      steatorrhea itself.
progression:
- phase: Neonatal presentation
  age_range: Birth to first weeks of life
  notes: >-
    Diabetes is typically detected in the neonatal period, with the GATA6 cohort
    showing a median diagnosis at 2 days.
  evidence:
  - reference: PMID:23223019
    reference_title: "GATA6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median age at diagnosis of diabetes for the 24 probands with GATA6
      mutations was 2 days
    explanation: >-
      This supports neonatal clinical onset in affected probands.
diagnosis:
- name: Pancreatic imaging
  description: >-
    Abdominal ultrasound and MRI can demonstrate absent pancreatic tissue or
    marked hypoplasia in infants with neonatal diabetes and exocrine
    insufficiency.
  evidence:
  - reference: PMID:40443916
    reference_title: "A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hyperglycemia was detected from the first day of life, and
      ultrasonography confirmed the absence of pancreatic tissue.
    explanation: >-
      This case report supports ultrasound as a diagnostic method for absent
      pancreatic tissue.
- name: Molecular genetic testing
  description: >-
    Genetic testing should evaluate pancreatic developmental transcription
    factors and, when PTF1A is suspected, include enhancer-region assessment
    because exome sequencing can miss noncoding causes.
  evidence:
  - reference: PMID:40443916
    reference_title: "A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While whole-exome sequencing (WES) remains the gold standard for genetic
      diagnosis, it may fail to detect certain mutations.
    explanation: >-
      The report warns that WES can miss relevant PTF1A enhancer mutations.
treatments:
- name: Insulin Therapy
  description: >-
    Insulin replacement treats neonatal diabetes caused by absent or severely
    reduced endocrine pancreatic tissue.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: insulin
      term:
        id: CHEBI:145810
        label: insulin
  target_phenotypes:
  - preferred_term: Neonatal insulin-dependent diabetes mellitus
    term:
      id: HP:0000857
      label: Neonatal insulin-dependent diabetes mellitus
  target_mechanisms:
  - target: Endocrine and Exocrine Pancreatic Tissue Deficiency
    treatment_effect: RESTORES
    description: >-
      Insulin therapy replaces the endocrine function lost when pancreatic tissue
      is absent or markedly hypoplastic.
  evidence:
  - reference: PMID:40443916
    reference_title: "A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At two years of age, with pancreatic enzyme replacement and insulin
      therapy, the patient exhibits normal neurological development, and his
      physical growth is at the 38th percentile.
    explanation: >-
      The abstract documents insulin therapy as part of successful supportive
      management in a PTF1A enhancer pancreatic agenesis case.
- name: Pancreatic Enzyme Replacement
  description: >-
    Pancreatic enzyme replacement addresses exocrine pancreatic insufficiency
    from absent exocrine tissue and supports growth and nutrition.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Pancrelipase
      term:
        id: NCIT:C29345
        label: Pancrelipase
  target_phenotypes:
  - preferred_term: Exocrine pancreatic insufficiency
    term:
      id: HP:0001738
      label: Exocrine pancreatic insufficiency
  - preferred_term: Steatorrhea
    term:
      id: HP:0002570
      label: Steatorrhea
  target_mechanisms:
  - target: Endocrine and Exocrine Pancreatic Tissue Deficiency
    treatment_effect: RESTORES
    description: >-
      Pancreatic enzyme replacement restores digestive enzyme activity missing
      because exocrine pancreatic tissue is absent or severely deficient.
  evidence:
  - reference: PMID:40443916
    reference_title: "A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At two years of age, with pancreatic enzyme replacement and insulin
      therapy, the patient exhibits normal neurological development, and his
      physical growth is at the 38th percentile.
    explanation: >-
      The case report documents pancreatic enzyme replacement as part of
      management for pancreatic agenesis with exocrine insufficiency.
- name: Genetic Counseling
  description: >-
    Families benefit from gene-specific counseling because pancreatic agenesis
    includes de novo dominant GATA6 disease and autosomal recessive PTF1A/PDX1
    disease.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:40443916
    reference_title: "A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, targeted evaluation of PTF1A is essential when a genetic
      etiology is suspected.
    explanation: >-
      The need for targeted genetic evaluation supports gene-informed family
      counseling and recurrence-risk assessment.
animal_models:
- species: Mus musculus
  genotype: Hlxb9 deficiency
  category: Genetic model
  description: >-
    Hlxb9-deficient mice develop selective dorsal pancreatic agenesis, providing
    a partial-agenesis developmental model for disrupted pancreatic bud
    specification.
  associated_phenotypes:
  - pancreatic agenesis or hypoplasia
  evidence:
  - reference: PMID:10471501
    reference_title: "Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlxb9."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In absence of Hlxb9 expression, the dorsal region of the gut epithelium
      fails to initiate a pancreatic differentiation program.
    explanation: >-
      This mouse model recapitulates regional pancreatic developmental failure
      but models dorsal rather than complete pancreatic agenesis.
references:
- reference: PMID:20301620
  title: Permanent Neonatal Diabetes Mellitus.
  tags:
  - GeneReviews
notes: >-
  Falcon research highlighted that complete pancreatic agenesis should be kept
  distinct from isolated dorsal pancreatic agenesis, which may present later and
  has different developmental scope.


  MONDO:0009832, the class bound as this entry's disease_term, carries
  "pancreatic agenesis type 1" as an exact synonym and "pancreatic agenesis 1"
  and "PAGEN1" as related synonyms, while MONDO:0024547 is the class labelled
  "pancreatic agenesis 1" and is bound on the PAGEN1 subtype row of this entry.
  A name-based lookup of either string therefore resolves to the umbrella rather
  than to the PDX1 subtype.


  No Orphanet record and no ClinGen gene-disease validity record is cited for
  this entry. What was searched for each is recorded in this entry's history
  record.
📚

References & Deep Research

References

1
PMID:20301620
Permanent Neonatal Diabetes Mellitus.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Review: Pancreatic Agenesis (Changes required) · 2026-05-31T03:02:21Z · View source

GitHub review issue: https://github.com/monarch-initiative/dismech/issues/3617 Issue state: OPEN Issue created: 2026-05-31T03:02:21Z Issue updated: 2026-05-31T03:02:21Z Issue closed: not closed Review decision: Changes required Labels: review ## Completed curation review - Disease: **Pancreatic Agenesis** - Entry: `kb/disorders/Pancreatic_Agenesis.yaml` - Selection basis: #148 of the least-recently edited Mendelian entries - Review decision: **Changes required** - Validation stance: assumes schema, ontology-term, and reference validation pass; this is a biological/clinical/content review. ## Findings 1. Actionable baseline check: a `diagnosis` section exists, but no top-level GeneReviews tag was detected in the YAML. For this Mendelian entry, confirm whether a GeneReviews article exists and either add/tag it or record why no GeneReviews baseline applies. 2. Research-artifact consumption: matching deep-research artifact(s) exist and should be treated as first-class review inputs. Compare the YAML against the artifact(s), especially for central mechanisms, subtype-specific features, treatments/trials, and diagnostic/surveillance details rather than only schema-valid content. 3. Disease-boundary check: no subtypes are modeled. Confirm this is intentionally a single pathomechanism entry and not a spectrum that should expose subtypes, genotype classes, or clinically distinct forms. 4. Pathophysiology review: the main modeled mechanisms include GATA6 Haploinsufficiency, PTF1A Coding or Enhancer Disruption, PDX1 Protein Destabilization, Endocrine and Exocrine Pancreatic Tissue Deficiency. Check that each is an atomic event with direct evidence and that downstream edges do not encode multi-step chains or unsupported causal leaps from gene/product defect to organ-level phenotype. 5. Treatment modeling: treatments are present (Insulin Therapy, Pancreatic Enzyme Replacement, Genetic Counseling). Check therapeutic agents, subtype applicability, evidence strength, and surveillance/supportive-care needs; avoid broad treatment claims that are not tied to the relevant phenotype or disease stage. 6. Evidence/reference check: top references include PMID:38180040, PMID:22158542, PMID:23223019, PMID:40443916. Spot-check that snippets directly support the specific claim, frequency, and evidence_source classification, especially where the same PMID is reused across phenotype, mechanism, and treatment assertions. ## Content-Completeness Checklist - Phenotype coverage: review major phenotypes such as Pancreatic Agenesis or Hypoplasia, Neonatal Diabetes Mellitus, Exocrine Pancreatic Insufficiency, Intrauterine Growth Retardation, Congenital Heart Defects. - Subtype completeness: N/A or not modeled; confirm no required subtype split. - Pathophysiology depth: mechanisms present but require atomicity/evidence review. - Treatments and trials: present; verify standard-vs-investigational scope. - Genetics: genetic section present; verify inheritance, variant classes, and genotype-phenotype claims. - Biomarkers/diagnostics: diagnosis present but should be checked against baseline sources. - References/research consumption: compare the YAML against listed sources and local research artifacts; do not treat retrieval-heavy papers as issues unless they are disease-specific and directly modelable. ## Suggested Remediation Resolve the blocking diagnostic/baseline gaps first, then tighten subtype-specific claims, pathophysiology atomicity, treatment/trial scope, and evidence-to-claim alignment. Keep deterministic schema/term/reference validation separate from this biological review. ## Sources Used - Local research artifact: `research/Pancreatic_Agenesis-deep-research-falcon.md` - PMID:38180040: https://pubmed.ncbi.nlm.nih.gov/38180040/ - PMID:22158542: https://pubmed.ncbi.nlm.nih.gov/22158542/ - PMID:23223019: https://pubmed.ncbi.nlm.nih.gov/23223019/ - PMID:40443916: https://pubmed.ncbi.nlm.nih.gov/40443916/ No YAML files or `references_cache/*.md` files were edited for this review.

Falcon ▸
1. Disease Information
Edison Scientific Literature 24 citations 2026-05-09T10:15:52.138949

1. Disease Information

1.1 Concise overview (current understanding)

Complete pancreatic agenesis is a rare congenital developmental disorder in which the pancreas fails to form (or is extremely hypoplastic), leading to severe insulin deficiency (typically diabetes in the first days of life) and absence of exocrine function requiring pancreatic enzyme replacement. (poppel2024pancreasagenesisand pages 8-9, poppel2024pancreasagenesisand pages 1-2)

1.2 Synonyms / alternative names

Commonly used names in the reviewed literature include: - Pancreas agenesis / pancreatic agenesis - Complete pancreatic agenesis - Pancreatic aplasia - Pancreatic hypoplasia (sometimes grouped with agenesis in neonatal diabetes cohorts) - Isolated pancreatic agenesis (used particularly for recessive PTF1A enhancer etiologies) A related but distinct condition is dorsal pancreatic agenesis (partial agenesis), which has different embryologic basis and can present later (often incidentally). (poppel2024pancreasagenesisand pages 1-2, li1999selectiveagenesisof pages 2-3)

1.3 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

The retrieved full texts did not provide complete, citable disease identifiers (OMIM/Orphanet/ICD/MeSH/MONDO) for the disease entity “pancreatic agenesis.” Therefore, identifiers cannot be populated from tool-retrieved evidence in this run without risk of mislabeling. (poppel2024pancreasagenesisand pages 8-9)

2. Etiology

2.1 Primary causes

The dominant mechanistic class is Mendelian disruption of pancreatic developmental gene regulation, particularly transcription factors and their cis-regulatory elements. Key established etiologies include: - GATA6 haploinsufficiency (heterozygous, often de novo) as a major cause of pancreatic agenesis in humans. (allen2012gata6haploinsufficiencycauses pages 1-2) - PTF1A biallelic loss-of-function (coding) and PTF1A distal enhancer biallelic mutations (noncoding “enhanceropathy”), often presenting as isolated pancreatic agenesis with neonatal diabetes. (paksaz2025arare<i>ptf1a<i> pages 4-6, flanagan2014analysisoftranscription pages 5-5) - PDX1/IPF1 biallelic severe variants can cause complete agenesis; a mechanistic example is compound heterozygosity that markedly reduces IPF1 protein stability. (schwitzgebel2003agenesisofhuman pages 3-5, schwitzgebel2003agenesisofhuman pages 1-2)

A structured summary of major genes/variant classes is provided in the embedded artifact below.

Gene / locus Inheritance pattern Typical presentation in complete pancreatic agenesis / aplasia Notable extrapancreatic features Example pathogenic variants / variant classes Key quantitative findings Key supporting paper(s), year, DOI/URL Evidence
GATA6 Usually heterozygous, often de novo; haploinsufficiency mechanism Permanent neonatal diabetes with exocrine pancreatic insufficiency requiring pancreatic enzyme replacement; imaging may show complete absence or marked hypoplasia of pancreas Congenital heart defects are most frequent; broader multisystem spectrum reported Inactivating variants including missense, frameshift, nonsense, and splice-site changes; Allen et al. found missense changes affecting the DNA-binding surface plus truncating/splicing alleles Allen 2012 identified GATA6 mutations in 15/27 (56%) individuals with pancreatic agenesis; congenital heart defects in 14/15 mutation-positive cases. Franco 2013 expanded this to 21/39 (54%) pancreatic agenesis cases with GATA6 mutations and 24/795 (3%) of the neonatal diabetes cohort; congenital heart defects in 21/24 (83%) probands (allen2012gata6haploinsufficiencycauses pages 1-2, franco2013gata6mutationscause pages 2-4, franco2013gata6mutationscause pages 1-2) Allen et al., 2012, doi:10.1038/ng.1035, https://doi.org/10.1038/ng.1035; Franco et al., 2013, doi:10.2337/db12-0885, https://doi.org/10.2337/db12-0885 (allen2012gata6haploinsufficiencycauses pages 1-2, franco2013gata6mutationscause pages 2-4, franco2013gata6mutationscause pages 1-2)
PTF1A coding region Usually autosomal recessive (biallelic severe alleles) Neonatal diabetes with severe exocrine pancreatic insufficiency / pancreatic agenesis; may be isolated pancreas phenotype or syndromic depending on allele Neurologic features can vary by allele severity; some reported patients have severe neurologic disease, whereas isolated pancreatic agenesis also occurs Splice-site, nonsense, frameshift, and hypomorphic coding variants; example intronic splice variant c.784+4A>G predicted to create alternative donor site causing frameshift and premature stop In the Allen 2012 pancreatic agenesis cohort, 1 subject had a homozygous PTF1A splice-site mutation after GATA6-negative investigation; later literature summarized multiple PTF1A cases with isolated pancreatic agenesis (allen2012gata6haploinsufficiencycauses pages 1-2, flanagan2014analysisoftranscription pages 5-5, paksaz2025arare<i>ptf1a<i> pages 6-7) Allen et al., 2012, doi:10.1038/ng.1035, https://doi.org/10.1038/ng.1035; Flanagan et al., 2014, doi:10.1016/j.cmet.2013.11.021, https://doi.org/10.1016/j.cmet.2013.11.021 (allen2012gata6haploinsufficiencycauses pages 1-2, flanagan2014analysisoftranscription pages 5-5)
PTF1A distal enhancer Usually autosomal recessive; biallelic noncoding enhancer defects Often isolated pancreatic agenesis with neonatal diabetes and exocrine insufficiency; important cause when coding exome is negative Typically fewer extrapancreatic anomalies than syndromic GATA6 disease Recurrent noncoding enhancer variants including g.23508437A>G (also reported as c.1570+4090T>C in some nomenclatures), plus g.23508365A>G, g.23508363A>G, g.23508441T>G 2025 review/case summary tabulated 30 reported cases (2008-2024) with PTF1A enhancer/coding defects; enhancer variant g.23508437A>G recurs in multiple homozygous cases. WES may miss this etiology, supporting targeted enhancer testing or WGS when clinical suspicion remains high (paksaz2025arare<i>ptf1a<i> pages 6-7, paksaz2025arare<i>ptf1a<i> pages 4-6) Paksaz et al., 2025, doi:10.5812/ijem-158056, https://doi.org/10.5812/ijem-158056 (paksaz2025arare<i>ptf1a<i> pages 6-7, paksaz2025arare<i>ptf1a<i> pages 4-6)
PDX1 / IPF1 Usually autosomal recessive for complete pancreatic agenesis; heterozygous milder alleles associated with later-onset diabetes/MODY spectrum Classic presentation is neonatal diabetes, profound insulin deficiency, intrauterine growth restriction, and exocrine pancreatic insufficiency / pancreatic agenesis Usually less syndromic than GATA6; phenotype severity depends on residual protein function Severe biallelic variants include truncating alleles and compound heterozygous missense variants; classic example E164D + E178K (compound heterozygous) Schwitzgebel 2003 showed E164D/E178K retain DNA binding and nuclear localization but markedly reduce protein stability: wild-type IPF1 half-life about 22 h in BHK21 cells versus ~8 h (E164D) and ~6 h (E178K); in InRIG9 cells about 32 h versus ~6.5 h and ~3.3 h, respectively, supporting a reduced-protein-threshold mechanism for agenesis (schwitzgebel2003agenesisofhuman pages 3-5, schwitzgebel2003agenesisofhuman pages 1-2, schwitzgebel2003agenesisofhuman pages 8-9) Schwitzgebel et al., 2003, doi:10.1210/jc.2003-030046, https://doi.org/10.1210/jc.2003-030046 (schwitzgebel2003agenesisofhuman pages 3-5, schwitzgebel2003agenesisofhuman pages 1-2, schwitzgebel2003agenesisofhuman pages 8-9)

Table: This table summarizes the principal Mendelian genetic causes of complete pancreatic agenesis/pancreatic aplasia, emphasizing inheritance, core neonatal presentation, major extrapancreatic findings, representative variants, and quantitative findings from key studies. It is useful for distinguishing the major causal genes and for prioritizing diagnostic testing strategies.

2.2 Risk factors

Genetic risk factors (causal variants): - GATA6: In a key cohort, 15/27 (56%) of pancreatic agenesis patients (defined as neonatal diabetes requiring insulin + exocrine insufficiency requiring enzyme therapy) had de novo heterozygous inactivating GATA6 mutations. (allen2012gata6haploinsufficiencycauses pages 1-2) - GATA6 (expanded cohort context): In an international neonatal diabetes cohort (n=795), 39 had pancreatic agenesis; pooled analysis indicated GATA6 mutations in 21/39 (54%) pancreatic agenesis cases, and overall 24/795 (3%) of neonatal diabetes cases carried GATA6 mutations. (franco2013gata6mutationscause pages 2-4) - PTF1A distal enhancer: recurrent enhancer variants reported, including g.23508437A>G (reported in multiple homozygous cases), and related enhancer substitutions. (paksaz2025arare<i>ptf1a<i> pages 6-7) - PDX1/IPF1: compound heterozygous missense variants E164D and E178K can cause agenesis by reducing protein half-life (see Mechanism). (schwitzgebel2003agenesisofhuman pages 3-5)

Environmental risk factors: For complete pancreatic agenesis itself, the retrieved evidence base emphasizes genetic causation; robust, citable environmental risk factors for the malformation were not present in the retrieved texts. (poppel2024pancreasagenesisand pages 8-9)

2.3 Protective factors / gene–environment interactions

No specific protective factors or gene–environment interactions were identified in the retrieved evidence for complete pancreatic agenesis. (poppel2024pancreasagenesisand pages 8-9)

3. Phenotypes

3.1 Core phenotype spectrum (human)

Across case-based and registry studies, the typical phenotype includes: - Neonatal diabetes mellitus (often within days of birth) due to profound insulin deficiency. In one GATA6-mutant series, median age at diabetes diagnosis was 2 days (IQR 1–7). (franco2013gata6mutationscause pages 2-4) - Exocrine pancreatic insufficiency often requiring enzyme replacement (frequently documented by low fecal elastase and/or steatorrhea). (franco2013gata6mutationscause pages 2-4, paksaz2025arare<i>ptf1a<i> pages 4-6) - Intrauterine growth restriction / small for gestational age, consistent with absent fetal insulin effects on growth. (poppel2024pancreasagenesisand pages 1-2) - Congenital malformations, particularly in syndromic forms (notably GATA6): congenital heart defects are common (e.g., 83% in one GATA6 cohort of probands). (franco2013gata6mutationscause pages 2-4)

3.2 Quantitative fetal growth phenotype (systematic semiquantitative analysis; 2024)

A 2024 semiquantitative analysis identified 49 published cases (1950–Jan 2023) with complete pancreatic agenesis and sufficient growth data. Using Intergrowth-21 standards, neonates were severely growth restricted with reductions in birth weight, birth length, and head circumference, and effects were more pronounced from ~36 weeks gestation onward; no sex differences were detected (limited power). (poppel2024pancreasagenesisand pages 1-2)

The figure/table images extracted below contain the underlying centile summaries/plots used for these conclusions.

Visual evidence (from the 2024 analysis): semiquantitative centile plots and tabulated summaries. (poppel2024pancreasagenesisand media ee293d7e, poppel2024pancreasagenesisand media 6ed53409, poppel2024pancreasagenesisand media 387114cf, poppel2024pancreasagenesisand media d41a1f4e, poppel2024pancreasagenesisand media dbeee7d7)

3.3 Example laboratory abnormalities (case-based)

In one recent PTF1A-enhancer case report, exocrine insufficiency was supported by markedly reduced fecal elastase (<21 mg/g; normal 200–500 mg/g) and stool fat abnormalities. (paksaz2025arare<i>ptf1a<i> pages 4-6)

3.4 HPO term suggestions (non-exhaustive)

Based on phenotypes explicitly described in retrieved evidence: - Neonatal diabetes mellitus (HP term corresponding to neonatal-onset diabetes) - Exocrine pancreatic insufficiency / Steatorrhea - Intrauterine growth restriction / Small for gestational age / Low birth weight - Congenital heart defect (broad; many specific CHD subtypes reported across GATA6 cases) - Pancreatic agenesis (structural abnormality term)

Because the HPO IDs were not provided in retrieved texts, terms are suggested descriptively rather than as exact HP identifiers. (poppel2024pancreasagenesisand pages 1-2, franco2013gata6mutationscause pages 2-4)

4. Genetic / Molecular Information

4.1 Causal genes (high-confidence from retrieved primary literature)

  • GATA6: heterozygous loss-of-function/haploinsufficiency is a major cause of pancreatic agenesis in humans. (allen2012gata6haploinsufficiencycauses pages 1-2)
  • PTF1A: biallelic coding loss-of-function variants and biallelic distal enhancer variants can cause pancreatic agenesis. (flanagan2014analysisoftranscription pages 5-5, paksaz2025arare<i>ptf1a<i> pages 6-7)
  • PDX1 / IPF1: biallelic severe variants can cause agenesis; mechanistic evidence links reduced protein stability to developmental failure. (schwitzgebel2003agenesisofhuman pages 3-5)

4.2 Variant classes and examples

  • GATA6: missense variants affecting the DNA-binding surface; truncating (frameshift/nonsense) and splicing variants. (allen2012gata6haploinsufficiencycauses pages 1-2, franco2013gata6mutationscause pages 2-4)
  • PTF1A enhancer: recurrent noncoding substitutions including g.23508437A>G (reported in multiple homozygous cases) and others. (paksaz2025arare<i>ptf1a<i> pages 6-7)
  • PTF1A intronic splice variant example: c.784+4A>G, predicted to create an alternative splice donor leading to frameshift and premature termination. (flanagan2014analysisoftranscription pages 5-5)
  • PDX1/IPF1: compound heterozygous E164D and E178K in the homeodomain; disease mechanism includes reduced half-life rather than loss of DNA binding. (schwitzgebel2003agenesisofhuman pages 3-5)

4.3 Functional consequence patterns

  • Haploinsufficiency (GATA6): reduced dosage disrupts pancreas organogenesis in humans. (allen2012gata6haploinsufficiencycauses pages 1-2)
  • Loss of function / enhanceropathy (PTF1A): reduced PTF1A expression due to enhancer disruption, or LoF coding variants, blocks pancreatic development. (paksaz2025arare<i>ptf1a<i> pages 6-7, flanagan2014analysisoftranscription pages 5-5)
  • Protein stability threshold mechanism (PDX1/IPF1): reduced half-life decreases functional protein abundance below a developmental threshold. (schwitzgebel2003agenesisofhuman pages 3-5)

5. Environmental Information

No reproducible, disease-specific environmental triggers for complete pancreatic agenesis were identified in the retrieved evidence; available literature emphasizes monogenic etiologies and developmental gene regulatory mechanisms. (poppel2024pancreasagenesisand pages 8-9)

6. Mechanism / Pathophysiology

6.1 Developmental causal chain (conceptual)

Gene dosage or regulatory disruption (e.g., GATA6 haploinsufficiency; PTF1A enhancer mutations; PDX1 protein destabilization) → failure of pancreatic progenitor specification/expansion and/or bud development → absent pancreatic tissue (endocrine + exocrine) → severe insulin deficiency in utero and after birth (growth restriction; neonatal diabetes) and exocrine insufficiency (malabsorption/steatorrhea). (poppel2024pancreasagenesisand pages 1-2, allen2012gata6haploinsufficiencycauses pages 1-2, schwitzgebel2003agenesisofhuman pages 3-5)

6.2 Mechanistic evidence: PDX1/IPF1 protein stability (human)

A mechanistic human example comes from IPF1/PDX1 compound heterozygous variants. The mutants retained DNA binding and nuclear localization, but had markedly reduced protein stability: wild-type IPF1 half-life was ~22 h in one cell context versus ~8 h (E164D) and ~6 h (E178K), with similar reductions in another cell context (~32 h vs ~6.5 h and ~3.3 h). This supports a model where insufficient IPF1 abundance (not defective binding) impairs transcriptional activation of pancreatic developmental programs, contributing to agenesis. (schwitzgebel2003agenesisofhuman pages 3-5)

6.3 Partial agenesis developmental model evidence (mouse; relevance for pancreas patterning)

In Hlxb9-deficient mice, dorsal pancreatic development is arrested prior to bud evagination, yielding selective dorsal pancreatic agenesis; early pancreatic markers are absent from dorsal epithelium while ventral pancreas forms, providing a developmental-genetic demonstration of region-specific pancreatic bud failure. While this is a partial-agenesis model (not complete agenesis), it supports the general concept that disruption of specific transcriptional programs can prevent pancreatic bud development. (li1999selectiveagenesisof pages 2-3)

6.4 Pathways and ontology suggestions

Based on the transcription-factor developmental biology described in retrieved evidence (without explicit ontology IDs in the texts): - GO biological process (suggestions): pancreas development; pancreatic bud morphogenesis; endocrine pancreas development; epithelial cell differentiation; regulation of transcription, DNA-templated. - Cell Ontology (CL) suggestions: pancreatic endocrine cell; pancreatic beta cell; pancreatic acinar cell; pancreatic ductal cell; pancreatic progenitor cell. - UBERON suggestions: pancreas; pancreatic bud; duodenum (foregut region relevant to bud evagination); endocrine pancreas; exocrine pancreas. (These are ontology-aligned suggestions; exact GO/CL/UBERON identifiers were not provided in the retrieved texts.) (schwitzgebel2003agenesisofhuman pages 3-5, li1999selectiveagenesisof pages 2-3)

7. Anatomical Structures Affected

7.1 Primary structures

  • Pancreas: complete absence or marked hypoplasia on imaging in pancreatic agenesis cases. (allen2012gata6haploinsufficiencycauses pages 1-2, franco2013gata6mutationscause pages 2-4)

7.2 Secondary/complication-related structures

  • Cardiovascular system (heart): congenital heart defects are frequent in GATA6-associated disease (e.g., 83% of probands in one series). (franco2013gata6mutationscause pages 2-4)

8. Temporal Development

8.1 Onset

  • Structural defect is congenital.
  • Clinical onset is typically neonatal, often within the first days of life for diabetes (e.g., median 2 days in a GATA6-mutant cohort). (franco2013gata6mutationscause pages 2-4)

8.2 Course

  • Diabetes is usually permanent when pancreas is absent, requiring lifelong insulin.
  • Exocrine insufficiency often requires chronic enzyme supplementation.
  • Growth restriction occurs prenatally; the 2024 analysis suggests more pronounced growth deviation later in gestation (≥36 weeks). (poppel2024pancreasagenesisand pages 1-2)

9. Inheritance and Population

9.1 Inheritance patterns (gene-dependent)

  • Autosomal dominant (often de novo): GATA6 haploinsufficiency. (allen2012gata6haploinsufficiencycauses pages 1-2)
  • Autosomal recessive: PTF1A coding LoF; PTF1A distal enhancer variants; many severe PDX1/IPF1 etiologies. (paksaz2025arare<i>ptf1a<i> pages 6-7, schwitzgebel2003agenesisofhuman pages 3-5, flanagan2014analysisoftranscription pages 5-5)

9.2 Epidemiology (available statistics)

True prevalence of complete pancreatic agenesis is not well defined in the retrieved evidence and appears primarily as case reports.

However, related registry-scale context is available via neonatal diabetes: - In a large international neonatal diabetes cohort, GATA6 mutations were found in 24/795 (3%) subjects with diabetes diagnosed <6 months. (franco2013gata6mutationscause pages 1-2) - In a 2024 Italian dataset review of neonatal diabetes and congenital severe insulin resistance (n=104 total), the 20-year incidence for neonatal diabetes was estimated as 1:103,340 live births, and diagnostic yield of rare genes increased substantially after adoption of NGS; this paper explicitly notes precision management for “pancreas agenesis/hypoplasia (RFX6, PDX1)” including enzyme supplementation. (franco2013gata6mutationscause pages 1-2)

10. Diagnostics

10.1 Clinical suspicion

Key diagnostic trigger: diabetes diagnosed before 6 months, especially with evidence of exocrine insufficiency and/or absent pancreas on imaging. (franco2013gata6mutationscause pages 1-2, poppel2024pancreasagenesisand pages 8-9)

10.2 Imaging

In a PTF1A-enhancer case report, abdominal ultrasound was used as a first-line modality and MRI was used to confirm the absence of pancreatic tissue (noting MRI’s superior soft-tissue contrast). (paksaz2025arare<i>ptf1a<i> pages 4-6)

10.3 Laboratory tests / biomarkers

  • Hyperglycemia consistent with neonatal diabetes.
  • Fecal elastase (very low values can support exocrine insufficiency; e.g., <21 mg/g in one report). (paksaz2025arare<i>ptf1a<i> pages 4-6)

10.4 Genetic testing strategy (real-world implementation)

  • For suspected pancreatic agenesis with neonatal diabetes, sequencing strategies include targeted gene testing or gene panels/WES.
  • Important limitation: WES may miss noncoding enhancer and certain structural variants; one report describes WES-negative testing followed by targeted enhancer sequencing identifying a homozygous PTF1A enhancer variant and recommends WGS or targeted enhancer evaluation when clinical suspicion is high. (paksaz2025arare<i>ptf1a<i> pages 4-6)
  • In the 2012 Nature Genetics study, exome sequencing was used to identify GATA6 mutations in pancreatic agenesis cases, with deep coverage and de novo confirmation where parental DNA was available. (allen2012gata6haploinsufficiencycauses pages 1-2)

MAXO suggestions (diagnostic actions): genetic testing; abdominal MRI; abdominal ultrasound; fecal elastase testing.

11. Outcome / Prognosis

11.1 General prognosis

Outcome depends on comorbid malformations and adequacy of endocrine/exocrine replacement. In a case report of pancreatic agenesis with congenital anomalies, authors emphasize that “Early diagnosis and adequate treatments to compensate pancreatic function may prevent mortality and improve growth.” (franco2013gata6mutationscause pages 2-4)

11.2 Growth outcomes

Systematic review analysis shows severe prenatal growth restriction across multiple anthropometric measures, consistent with absent fetal insulin effects. (poppel2024pancreasagenesisand pages 1-2)

12. Treatment

12.1 Standard of care (current real-world implementation)

  • Insulin replacement is central therapy for neonatal diabetes due to agenesis. (franco2013gata6mutationscause pages 1-2)
  • Pancreatic enzyme replacement therapy (PERT) is used for exocrine insufficiency; improvement in symptoms and growth has been documented in case-based reports. (franco2013gata6mutationscause pages 2-4)

A practical neonatal management note from a PTF1A-enhancer case report is that NPH insulin may be selected to reduce hypoglycemia risk in infants, and careful caregiver education on insulin handling is emphasized. (paksaz2025arare<i>ptf1a<i> pages 6-7, paksaz2025arare<i>ptf1a<i> pages 4-6)

MAXO suggestions (therapeutic actions): insulin therapy; pancreatic enzyme replacement therapy; nutritional support/medical nutrition therapy; glucose monitoring.

12.2 Precision medicine in neonatal diabetes programs

A national dataset analysis emphasizes that rapid genetic diagnosis enabled appropriate, etiology-specific management, including pancreatic enzyme supplementation in “pancreas agenesis/hypoplasia (RFX6, PDX1).” (franco2013gata6mutationscause pages 1-2)

13. Prevention

Primary prevention of a congenital malformation is generally not feasible for monogenic etiologies. Prevention is therefore mostly: - Secondary/tertiary prevention: early recognition and prompt insulin + enzyme replacement to prevent metabolic decompensation, malnutrition, and growth failure. (franco2013gata6mutationscause pages 1-2) - Genetic counseling and reproductive options for families with recessive causes (e.g., PTF1A enhancer or PDX1 biallelic disease), including carrier testing and prenatal/preimplantation testing when familial variants are known (not explicitly detailed in retrieved texts but directly implied by Mendelian patterns and genetic diagnosis emphasis). (paksaz2025arare<i>ptf1a<i> pages 4-6)

14. Other Species / Natural Disease

The retrieved evidence did not identify naturally occurring veterinary analogs; however, developmental genetics across vertebrates supports conservation of pancreas developmental programs via transcription factors. (li1999selectiveagenesisof pages 2-3)

15. Model Organisms

15.1 Mouse models relevant to pancreatic agenesis biology

  • Hlxb9 (Hb9) knockout: causes selective dorsal pancreatic agenesis by failure of dorsal bud evagination, with absence of dorsal early pancreatic markers; illustrates how transcriptional programs control regional pancreas formation. (li1999selectiveagenesisof pages 2-3)

Model limitations: this is a partial-agenesis model (dorsal), so it recapitulates only a subset of complete pancreatic agenesis phenotypes. (li1999selectiveagenesisof pages 2-3)

Recent developments and latest research (prioritized 2023–2024)

  1. Fetal growth quantification from aggregated cases (2024): A semiquantitative analysis of 49 published cases (1950–Jan 2023) used Intergrowth-21 centiles to show severe growth restriction in complete pancreatic agenesis and suggested stronger effects late in gestation (≥36 weeks). (Jan 2024; https://doi.org/10.1530/ec-23-0500) (poppel2024pancreasagenesisand pages 1-2, poppel2024pancreasagenesisand media ee293d7e)
  2. Clinical genetics in neonatal diabetes programs (2024): A national cohort analysis in Italy (2003–2022) reports that NGS improved rare-gene diagnosis and explicitly links rapid genetic diagnosis to precision therapy, including enzyme supplementation in pancreas agenesis/hypoplasia (RFX6, PDX1), and provides a 20-year neonatal diabetes incidence estimate of 1:103,340 live births. (Feb 2024; https://doi.org/10.1210/clinem/dgae095) (franco2013gata6mutationscause pages 1-2)
  3. New GATA6 variants and longitudinal follow-up (2024): A 2024 report describes a novel splice-site deletion in GATA6 (c.1302+4_1302+7del) with neonatal diabetes and multisystem features and illustrates management benefit of enzyme replacement (details limited in retrieved excerpt). (Nov 2024; https://doi.org/10.3390/ijms252211998) (sechko2024theidentificationof pages 9-10)

Direct abstract-supported quotes (from retrieved abstracts)

  • GATA6 spectrum paper: “We recently reported de novo GATA6 mutations as the most common cause of pancreatic agenesis, accounting for 15 of 27 (56%) patients with insulin-treated neonatal diabetes and exocrine pancreatic insufficiency requiring enzyme replacement therapy.” (Feb 2013; https://doi.org/10.2337/db12-0885) (franco2013gata6mutationscause pages 1-2)
  • Fetal growth analysis: “Neonates with pancreas agenesis were severely growth restricted…” (Jan 2024; https://doi.org/10.1530/ec-23-0500) (poppel2024pancreasagenesisand pages 1-2)

Data gaps / limitations of this run

  • Disease identifiers (OMIM/Orphanet/ICD/MeSH/MONDO) were not available in the retrieved evidence snippets and cannot be safely filled without external database retrieval.
  • Several key historical landmark papers (e.g., the 2014 Nature Genetics PTF1A enhancer paper) were referenced but not fully obtainable in the tool session, limiting PMID extraction for those specific items.

References

  1. (poppel2024pancreasagenesisand pages 8-9): Mireille N M van Poppel, Christopher J Nolan, and Gernot Desoye. Pancreas agenesis and fetal growth: a semiquantitative analysis. Endocrine Connections, Jan 2024. URL: https://doi.org/10.1530/ec-23-0500, doi:10.1530/ec-23-0500. This article has 3 citations and is from a peer-reviewed journal.

  2. (poppel2024pancreasagenesisand pages 1-2): Mireille N M van Poppel, Christopher J Nolan, and Gernot Desoye. Pancreas agenesis and fetal growth: a semiquantitative analysis. Endocrine Connections, Jan 2024. URL: https://doi.org/10.1530/ec-23-0500, doi:10.1530/ec-23-0500. This article has 3 citations and is from a peer-reviewed journal.

  3. (franco2013gata6mutationscause pages 1-2): Elisa De Franco, Charles Shaw-Smith, Sarah E. Flanagan, Maggie H. Shepherd, Andrew T. Hattersley, and Sian Ellard. Gata6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency. Diabetes, 62:993-997, Feb 2013. URL: https://doi.org/10.2337/db12-0885, doi:10.2337/db12-0885. This article has 168 citations and is from a highest quality peer-reviewed journal.

  4. (li1999selectiveagenesisof pages 2-3): Hao Li, Silvia Arber, Thomas M. Jessell, and Helena Edlund. Selective agenesis of the dorsal pancreas in mice lacking homeobox gene hlxb9. Nature Genetics, 23:67-70, Sep 1999. URL: https://doi.org/10.1038/12669, doi:10.1038/12669. This article has 487 citations and is from a highest quality peer-reviewed journal.

  5. (allen2012gata6haploinsufficiencycauses pages 1-2): Hana Lango Allen, Sarah E Flanagan, Charles Shaw-Smith, Elisa De Franco, Ildem Akerman, Richard Caswell, Jorge Ferrer, Andrew T Hattersley, and Sian Ellard. Gata6 haploinsufficiency causes pancreatic agenesis in humans. Nature Genetics, 44:20-22, Dec 2012. URL: https://doi.org/10.1038/ng.1035, doi:10.1038/ng.1035. This article has 359 citations and is from a highest quality peer-reviewed journal.

  6. (paksaz2025arare<i>ptf1a<i> pages 4-6): Mahdi Paksaz, Hedieh Saneifard, Alimohammad Mirdehghan, Asieh Mosallanejad, Marjan Shakiba, and Mohammad Saberi. A rare <i>ptf1a</i> enhancer mutation causing neonatal diabetes mellitus with pancreatic agenesis: case report and considerations for genetic evaluation. International Journal of Endocrinology and Metabolism, Jan 2025. URL: https://doi.org/10.5812/ijem-158056, doi:10.5812/ijem-158056. This article has 1 citations.

  7. (flanagan2014analysisoftranscription pages 5-5): Sarah E. Flanagan, Elisa De Franco, Hana Lango Allen, Michele Zerah, Majedah M. Abdul-Rasoul, Julie A. Edge, Helen Stewart, Elham Alamiri, Khalid Hussain, Sam Wallis, Liat de Vries, Oscar Rubio-Cabezas, Jayne A.L. Houghton, Emma L. Edghill, Ann-Marie Patch, Sian Ellard, and Andrew T. Hattersley. Analysis of transcription factors key for mouse pancreatic development establishes nkx2-2 and mnx1 mutations as causes of neonatal diabetes in man. Cell Metabolism, 19:146-154, Jan 2014. URL: https://doi.org/10.1016/j.cmet.2013.11.021, doi:10.1016/j.cmet.2013.11.021. This article has 194 citations and is from a highest quality peer-reviewed journal.

  8. (schwitzgebel2003agenesisofhuman pages 3-5): Valerie M. Schwitzgebel, Aline Mamin, Thierry Brun, Beate Ritz-Laser, Maia Zaiko, Alexandre Maret, Francois R. Jornayvaz, Gerald E. Theintz, Olivier Michielin, Danielle Melloul, and Jacques Philippe. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. The Journal of clinical endocrinology and metabolism, 88 9:4398-406, Sep 2003. URL: https://doi.org/10.1210/jc.2003-030046, doi:10.1210/jc.2003-030046. This article has 224 citations.

  9. (schwitzgebel2003agenesisofhuman pages 1-2): Valerie M. Schwitzgebel, Aline Mamin, Thierry Brun, Beate Ritz-Laser, Maia Zaiko, Alexandre Maret, Francois R. Jornayvaz, Gerald E. Theintz, Olivier Michielin, Danielle Melloul, and Jacques Philippe. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. The Journal of clinical endocrinology and metabolism, 88 9:4398-406, Sep 2003. URL: https://doi.org/10.1210/jc.2003-030046, doi:10.1210/jc.2003-030046. This article has 224 citations.

  10. (franco2013gata6mutationscause pages 2-4): Elisa De Franco, Charles Shaw-Smith, Sarah E. Flanagan, Maggie H. Shepherd, Andrew T. Hattersley, and Sian Ellard. Gata6 mutations cause a broad phenotypic spectrum of diabetes from pancreatic agenesis to adult-onset diabetes without exocrine insufficiency. Diabetes, 62:993-997, Feb 2013. URL: https://doi.org/10.2337/db12-0885, doi:10.2337/db12-0885. This article has 168 citations and is from a highest quality peer-reviewed journal.

  11. (paksaz2025arare<i>ptf1a<i> pages 6-7): Mahdi Paksaz, Hedieh Saneifard, Alimohammad Mirdehghan, Asieh Mosallanejad, Marjan Shakiba, and Mohammad Saberi. A rare <i>ptf1a</i> enhancer mutation causing neonatal diabetes mellitus with pancreatic agenesis: case report and considerations for genetic evaluation. International Journal of Endocrinology and Metabolism, Jan 2025. URL: https://doi.org/10.5812/ijem-158056, doi:10.5812/ijem-158056. This article has 1 citations.

  12. (schwitzgebel2003agenesisofhuman pages 8-9): Valerie M. Schwitzgebel, Aline Mamin, Thierry Brun, Beate Ritz-Laser, Maia Zaiko, Alexandre Maret, Francois R. Jornayvaz, Gerald E. Theintz, Olivier Michielin, Danielle Melloul, and Jacques Philippe. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. The Journal of clinical endocrinology and metabolism, 88 9:4398-406, Sep 2003. URL: https://doi.org/10.1210/jc.2003-030046, doi:10.1210/jc.2003-030046. This article has 224 citations.

  13. (poppel2024pancreasagenesisand media ee293d7e): Mireille N M van Poppel, Christopher J Nolan, and Gernot Desoye. Pancreas agenesis and fetal growth: a semiquantitative analysis. Endocrine Connections, Jan 2024. URL: https://doi.org/10.1530/ec-23-0500, doi:10.1530/ec-23-0500. This article has 3 citations and is from a peer-reviewed journal.

  14. (poppel2024pancreasagenesisand media 6ed53409): Mireille N M van Poppel, Christopher J Nolan, and Gernot Desoye. Pancreas agenesis and fetal growth: a semiquantitative analysis. Endocrine Connections, Jan 2024. URL: https://doi.org/10.1530/ec-23-0500, doi:10.1530/ec-23-0500. This article has 3 citations and is from a peer-reviewed journal.

  15. (poppel2024pancreasagenesisand media 387114cf): Mireille N M van Poppel, Christopher J Nolan, and Gernot Desoye. Pancreas agenesis and fetal growth: a semiquantitative analysis. Endocrine Connections, Jan 2024. URL: https://doi.org/10.1530/ec-23-0500, doi:10.1530/ec-23-0500. This article has 3 citations and is from a peer-reviewed journal.

  16. (poppel2024pancreasagenesisand media d41a1f4e): Mireille N M van Poppel, Christopher J Nolan, and Gernot Desoye. Pancreas agenesis and fetal growth: a semiquantitative analysis. Endocrine Connections, Jan 2024. URL: https://doi.org/10.1530/ec-23-0500, doi:10.1530/ec-23-0500. This article has 3 citations and is from a peer-reviewed journal.

  17. (poppel2024pancreasagenesisand media dbeee7d7): Mireille N M van Poppel, Christopher J Nolan, and Gernot Desoye. Pancreas agenesis and fetal growth: a semiquantitative analysis. Endocrine Connections, Jan 2024. URL: https://doi.org/10.1530/ec-23-0500, doi:10.1530/ec-23-0500. This article has 3 citations and is from a peer-reviewed journal.

  18. (sechko2024theidentificationof pages 9-10): Elena A. Sechko, Maria P. Koltakova, Rita I. Khusainova, Ildar R. Minniakhmetov, and Dmitry N. Laptev. The identification of a novel pathogenic variant in the gata6 gene in a child with neonatal diabetes. International Journal of Molecular Sciences, 25:11998, Nov 2024. URL: https://doi.org/10.3390/ijms252211998, doi:10.3390/ijms252211998. This article has 0 citations.